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Abstract 
Introduction: Abnormal blood coagulation, systemic inflammation and microbial dysbiosis are 
shared pathological characteristics of cardiovascular and neurodegenerative diseases. In 
addition, defective clotting processes and vascular complications are proposed as prominent 
links between these two disorders as they present simultaneously in respective patients. 
Another seemingly unrelated pathology that is seen associated with cardiovascular and 
neurodegenerative disease is periodontitis – a chronic inflammatory condition characterized 
by oral tissue degradation which is predominantly caused and driven by dysbiotic microbe 
populations. Out of several species of bacteria that have been identified to contribute to the 
pathogenesis of periodontal disease, Porphyromonas gingivalis – a gram negative anaerobe 
– has been deemed as a keystone pathogen capable of causing periodontitis in solitude. This
bacterium has been implicated in both cardiovascular disease (CVD) and neurodegeneration. 
In this current study, the aims are to identify an integral virulent product, specifically a protease 
called gingipain R1 (RgpA), from P. gingivalis in the blood of individuals suffering from 
neurodegeneration and determine the effects that this protease and lipopolysaccharide (LPS) 
from the same species impose on normostatic blood coagulation. Research on the effect of 
these bacterial inflammagens on clot kinetics, rheology and fibrin network formation is and 
thus emphasizes the novelty of this study. The primary neurodegenerative disease of choice 
is Parkinson’s disease (PD) as it is also significantly associated with periodontal pathologies 
and hence likely involves P. gingivalis infection exterior to the oral cavity. We also probed for 
its protease in the haematological system of patients with Alzheimer’s disease (AD), another 
neurodegenerative closely correlated to periodontitis. Identifying membrane components of 
this oral pathogen in the blood of PD patients, and other neurodegenerative diseases such as 
AD, is of particular importance and may provide further insight into the early pathogenesis and 
cardiovascular involvement in neurodegenerative disease as a whole. 
Aims and objectives: This thesis is divided into two main objectives. The first being the 
identification of a RgpA produced by P. gingivalis in blood samples of PD and AD patients; the 
second objective is to study the effects of this bacterium’s protease and LPS on coagulation 
using a healthy blood model and a purified fibrinogen model.  To achieve the first objective, 
the aim is to identify, using polyclonal antibodies against the protease in question, RgpA, in 
the blood of individuals suffering from PD and AD. To achieve the second objective of this 
study we characterized the effects of RgpA and LPS on blood coagulation kinetics and 
terminal fibrin network structure by using a healthy blood model as well as a purified fibrinogen 
model. The techniques utilized include thromboelastography, rheometry, confocal microscopy 
and scanning electron microscopy (SEM). 
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Results: Using a polyclonal antibody against RgpA, it is shown that RgpA is present in the 
haematological system of both a PD population and AD population; this finding was 
quantitatively significant (p < 0.0001) in both groups as measured via fluorescent intensity. 
Additionally, the impact of RgpA on the viscoelastic parameters of blood clotting is extensive. 
RgpA exerts an inhibitory effect on clot kinetics, increases the stiffness of fibrin networks and 
decreases the total clot load via fibrin(ogen)olytic mechanisms in platelet-poor plasma (PPP) 
and whole-blood (WB). In purified fibrinogen models, however, this effect was exaggerated as 
minimal or no fibrin formed after RgpA incubation. This effect was abrogated in the presence 
of LPS from P. gingivalis whereby a decrease in fibrin load was absent; however, LPS still 
induced anomalous clot formation characterized by dense matter deposits – a pathological 
form of fibrin networks.  
Conclusion: There exists a significant correlation between periodontitis and 
neurodegeneration, yet findings of P. gingivalis, the chief periodontopathic bacterium, in the 
blood of PD and AD patients are inexistent. Here, for the first time, it is demonstrated that 
RgpA is evidently present within the haematological system of individuals suffering from PD 
and AD. These findings pave way for a new view of neurodegenerative pathology and offers 
insight into prospective preventative and therapeutic interventions. Furthermore, RgpA may 
provide useful as a biomarker in these debilitating disorders and therefore requires such 
attention. In the context of the coagulation system, RgpA is highly active. In contrast to the 
general prothrombotic state observed in most chronic inflammatory conditions, RgpA seems 
to shift the normostatic state of coagulation to hypocoagulation. Furthermore, the proteolytic 
activity of this particular gingipain inhibits the formation of fibrin formed thereby decreasing the 
clot load, the total amount of fibrin formed. The magnitude of this effect differs in plasma and 
purified fibrinogen and most likely exits due to the presence of inhibitory and target molecules 
in plasma such as albumin and other proteins. Another important finding is that the proteolytic 
capability of RgpA is dampened in the presence of LPS from the same bacterial species which 
offers insight into realistic physiological functioning whereby LPS and gingipains are co-
secreted by P. gingivalis. These data emphasises the degree of influence that bacterial 
species and inflammagens have on the coagulation system, and highlights their presence in 
PD and AD. 
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CHAPTER 1: INTRODUCTION 
 
In the context of this thesis, it is assumed that the two neuro-inflammatory diseases, namely 
Parkinson’s and Alzheimer’s diseases are also characterized by the presence of systemic 
inflammation, and are thus referred to as inflammatory conditions. 
 
Inflammatory conditions such as Parkinson’s disease (PD) PD, Alzheimer’s disease (AD) and 
type II diabetes mellitus (T2DM) continue to burden the global healthcare as the leading 
causes of death (Pahwa and Jialal, 2019). These disorders are also significantly related in a 
comorbid manner (Ursum et al., 2013, Garcia-Olmos et al., 2012, Holmstrup et al., 2017), 
whereby cardiovascular (CVD) and its complications – according to the World Health 
Organisation (WHO) – is the leading cause of death in these inflammatory conditions. It is, in 
fact, well-known that most inflammatory diseases are also associated with a prothrombotic 
state prompted by aberrant coagulation (Herzberg, 2001, Bester and Pretorius, 2016, 
Randeria et al., 2019, Kell and Pretorius, 2015). In such inflammatory conditions, clotting 
defects contribute significantly to an occurrence of a cardiovascular event (Zhao and 
Schooling, 2018)  - a common mode of mortality among these patients (Vogelgsang et al., 
2018, Holmstrup et al., 2017, Ursum et al., 2013, Potashkin et al., 2019). Common to 
inflammatory diseases is also an impairment and/or over activity of immune function; this 
presents with the dysregulation of inflammatory cytokines including interleukin (IL) -1β, IL-6, 
IL-8, tumour necrosis factor (TNF)-α and CRP (Chen et al., 2018b, Bester and Pretorius, 
2016). This chronic, proinflammatory state is therefore a prominent driver of systemic (and 
neuro-) inflammation and further disease pathogenesis. Interestingly, systemic inflammation 
is a major link between the aforementioned chronic inflammatory conditions and poses as a 
principal target of clinical therapy (Bui et al., 2019, Straub and Schradin, 2016, Randeria et 
al., 2019). However, even though the contribution of immune dysfunction in chronic 
inflammatory conditions is well recognised, the complexity of pathophysiology, inefficacious 
treatment and overlapping mechanisms between comorbidities allows the prevalence of these 
disorders to grow.  
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A closer look at anomalous clotting in inflammatory conditions 
A major hallmark of systemic inflammation – a commonality among and driver of most 
systemic diseases (Biava and Norbiato, 2015, Hunter, 2012) – is a dysregulation of clotting 
processes which manifest as a hypercoagulable and hypofibrinolytic state (Foley and Conway, 
2016, Kell and Pretorius, 2015). Hypercoagulability entails the tendency of blood to undergo 
rapid, excessive clotting and acts as a major risk factor for thrombosis (Bridge et al., 2014). 
Hypofibrinolysis is characterised by a decreased degradation of fibrin clots (Kell and Pretorius, 
2015). These two phenomena contribute to an increased prothrombotic state and 
cardiovascular risk (Maino et al., 2015). This prothrombotic state poses as a therapeutic target 
that can significantly decrease cardiovascular complications and provide prognostic benefit 
(Smalberg et al., 2011, Kearney et al., 2017). It has been demonstrated that certain 
inflammatory cytokines, specifically IL-1β, IL-6 and IL-8, activates platelets and promote more 
rapid clot kinetics characteristic of a hypercoagulable state (Bester et al., 2018, Bester and 
Pretorius, 2016); these cytokines also increase the time taken for fibrin degradation thereby 
increasing the propensity of hypofibrinolysis (Bester et al., 2018). 
Both PD and AD have been denoted to exhibit abnormal coagulation (Rosenbaum et al., 2013, 
Pretorius et al., 2014, Suidan et al., 2018). Recently, analysis of clotting kinetics in PD and AD 
populations revealed a hypercoagulable state (Bester et al., 2015); furthermore, platelets 
exhibited phenotypes characteristic of hyperactivation (Adams et al., 2019). A hypercoaguable 
state in AD has also been elucidated. It was previously also shown that, in AD, a pathology 
hallmarked by amyloid β plaques, fibrinogen and amyloid β fragments amalgamate and 
subsequently increase amyloid β load, impaired cerebral blood flow and further 
neuroinflammation (Cortes-Canteli et al., 2012). This hypercoaguable state and fibrinogen 
dyshomeostasis, along with systemic inflammation, is responsible for the observed 
prothrombotic state observed in neurodegenerative disease (Gupta et al., 2005). In 
consideration of the impact that clotting defects exert on neurodegenerative disease, drugs 
targeting hypercoagulability, particularly in AD, has been developed (Maiese, 2015).  
Additionally, it was also shown that in PD and AD (as well as T2DM) the biochemical nature 
of fibrin(ogen) clots are atypical and exhibit the presence of amyloid fibrils (de Waal et al., 
2018, Pretorius et al., 2017b). In these diseases, lipopolysaccharide (LPS)-binding protein can 
be used as an intervention to ameliorate abnormal clotting seen in PD, AD and T2DM blood 
samples (Pretorius et al., 2018c, Pretorius et al., 2018a, Pretorius et al., 2017b). This opened 
a question, as to whether bacterial inflammagens like bacterial LPS might be one of the many 
novel circulating biomarkers that drive systemic inflammation, and whether LPS and other 
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bacterial membrane components (and thus microbial activity) may contribute to the clotting 
processes of PD and AD.  
Pathological clotting processes thus seem to be notably implicated in neurodegenerative 
disease and therefore possibly linked to neuropathology and cardiovascular mortality. 
Circulating bacterial inflammagens also seem to be important novel biomarkers for AD, PD 
and other inflammatory conditions. Therefore, further investigation into etiological factors and 
the possible role of bacterial inflammagens are thus required to reduce the burden of such 
pathophysiological mechanisms. The following section will discuss the latest research with 
regards to bacteria and/or their membrane components as drivers of pathology in systemic 
inflammatory conditions such as PD and AD. 
The implication of microbes in non-communicable disease 
Recently, microbes have been more widely implicated in non-communicable diseases (NCD) 
such as CVD (de Waal et al., 2018), AD (Poole et al., 2013), PD (Ranjan et al., 2018), T2DM 
(Sharma and Tripathi, 2019), rheumatoid arthritis (du Teil Espina et al., 2019) and respiratory 
disease (Bansal et al., 2013). It is known that many patients suffering from these chronic 
inflammatory conditions also suffer from gut dysbiosis, leaky gut (Obrenovich, 2018, Kell and 
Pretorius, 2018) and oral dysbiosis (Carding et al., 2015, Griffiths and Mazmanian, 2018) 
which manifests as periodontal disease (Winning and Linden, 2017, Bui et al., 2019).  
Periodontal lesions and ‘leaky’ gut epithelia may assist the entry of periodontopathic bacteria 
into the haematological system whereby their virulent and immunogenic constituents can act 
as potent inflammagens. This bacterial translocation phenomenon may account, in part, for 
the relation between bacterial inflammagens in circulation and the presence, in part, of 
systemic inflammation seen in the aforementioned inflammatory diseases. With the implication 
of microbes in chronic inflammatory conditions whereby defective coagulation associated, the 
question that this thesis aims to establish if bacterial membrane inflammagens are indeed 
present in inflammatory conditions such as PD and AD; and if these membrane inflammagens 
have a pathological effect on clotting processes.   
The question that now arises is if there is any evidence that specifically oral pathogen 
inflammagens might play a more central role in inflammatory conditions, particularly in PD and 
AD. 
Shifting focus to the oral microbiome 
While much focus has been aimed at the gut microbiome in the context of NCD, the oral 
microbiome is beginning to receive the attention it deserves due to its impact on systemic 
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(patho)physiology (Sudhakara et al., 2018). In oral pathology, the commensal community of 
organisms become dysregulated and shift their normostatic microbial profile to a dysbiotic one 
(Deng et al., 2017). This pathological community, dominated by bacteria, is what induces oral 
tissue degradation and overt periodontal disease. According to the WHO, the Global Burden 
of Disease Study 2016 estimated that oral disorders such as periodontitis and gingivitis affect 
half of the world’s population (close to 4 billion individuals) – a staggering statistic that calls 
for action, particularly against periodontopathic bacteria. Porphyromonas gingivalis – a gram 
negative, anaerobic bacterium that possesses an infamous inventory of virulent factors – is 
well recognised as a keystone pathogen capable of causing oral dysbiosis and ensuing 
chronic periodontitis (Darveau et al., 2012, Meuric et al., 2017). Interestingly, periodontal 
disease exhibits a tight relation with neurodegeneration in the form of PD and AD (Imamura 
et al., 2001a, Chistiakov et al., 2016, Cowan et al., 2019), and cardiovascular disease (Ilievski 
et al., 2018, Leishman et al., 2010). Periodontitis also presents with abnormalities in clotting 
processes and a subsequent prothrombotic state (Imamura et al., 2001a, Dikshit, 2015, Senini 
et al., 2019, Bizzarro et al., 2010). Periodontal pathogens – predominantly P. gingivalis – and 
their effect on ‘isolated’ clotting processes have been studied with detail by Imamura and 
colleagues (Imamura et al., 2001b, Imamura et al., 1997, Imamura et al., 2001a, Imamura et 
al., 2000, Imamura et al., 1995). However, a more comprehensive analysis using modern 
techniques such as thromboelastography, rheology, and microscopy would offer a more 
insight. Hence, detailing the role of periodontopathic bacteria on systemic coagulation is one 
of the objectives of this study. 
Is there a link between the presence of oral pathogens and impaired clotting? 
P. gingivalis infection has indeed been associated with impaired clotting and an increased 
thrombotic risk (Papapanagiotou et al., 2009, Zhan et al., 2016). Relevantly, P. gingivalis has 
been noted to enter circulation via dental procedures and more importantly periodontal lesions 
(Horliana et al., 2014) – a phenomenon which may account for the relation between oral and 
cardiovascular pathology. The bacterium has been found in atherosclerotic tissue (Kozarov et 
al., 2005, Velsko et al., 2014), vascular cells (Deshpande et al., 1998, Dorn et al., 2000, Olsen 
and Progulske-Fox, 2015) and cerebral clots of acute ischemic stroke patients (Patrakka et 
al., 2019). Also, periodontitis is significantly associated with PD and AD (Chen et al., 2017a, 
Laugisch et al., 2018, Kaur et al., 2016)  Interestingly, neither this bacterium nor its molecular 
signatures have yet been identified in the haematological system of individuals suffering from 
neurological disorders of which a strong correlation with periodontal disease stands (Cicciu, 
2016). However, numerous mice studies have found P. gingivalis disseminated in 
physiological systems exterior to the oral cavity (Velsko et al., 2014, Poole et al., 2015) which 
suggests its infection exterior to the oral cavity is likely. 
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Causative factors of this haematological disturbance includes dysregulated inflammatory 
markers (Adams et al., 2019, Gupta et al., 2005, Bester and Pretorius, 2016) and more 
relevant to this study, the presence and influence of microbial products such as 
lipopolysaccharide (LPS) and lipoteichoic acid (LTA) (Pretorius et al., 2016, Kastrup et al., 
2008, Borenstein, 2008). A recent study detected LPS from Escherichia coli associated with 
fibrin molecules in Parkinson’s and Alzheimer’s disease, as well as type II diabetes (de Waal 
et al., 2018). Apart from simply being present in the blood of these individuals, LPS has been 
shown to impact the kinetics of the clotting cascade resulting in hypercoagulability and cause 
aberrant fibrin network ultrastructure (Pretorius et al., 2016, Pretorius et al., 2018b). As a 
gram-negative bacterium P. gingivalis produces LPS. This species’ endotoxin also alters 
coagulation and has been shown to do so by activating platelets, causing their spreading and 
inducing hypercoagulability (Senini et al., 2019). Furthermore, this species’ LPS upregulates 
neuroinflammation and causes cognitive deficits in mice (Zhang et al., 2018). Hence, the 
influence of LPS and therefore microbial activity in neurodegeneration seems convincing. 
Room for a novel inflammagen? 
While the pathological activity of LPS is well recognised, there are other virulent factors – 
specific proteases called gingipains – produced by P. gingivalis that are deemed the pivotal 
factor to its pathogenicity (Guo et al., 2010). Gingipains are a group of cysteine proteolytic 
enzymes produced by various strains of P. gingivalis which are essential for this bacterium’s 
survival, nutrient acquisition, proliferation and success in terms of virulence (Sheets et al., 
2008, Jia et al., 2019). There exist three major forms of the enzyme: gingipain R1 (RgpA) and 
gingipain R2 (RgpB) which are both arginine-specific, as well as gingipain K (Kgp) which is 
lysine-specific (Li and Collyer, 2011). In oral health, these proteases degrade gingival tissue 
and give rise to periodontal lesions (Imamura, 2003). It should be noted that this chronic 
degradation of oral tissue acts as a route for microbes into the blood stream. With relevance 
to coagulation, gingipains have been shown to exert fibrin(ogen)olytic activity (Imamura et al., 
1995) – a phenomenon which epitomizes the essence of this study. Another function of these 
proteases is too interfere with the immune system and degrade (nullify) cytokines (Guo et al., 
2010, Slocum et al., 2016, Hajishengallis, 2011, Mezyk-Kopec et al., 2005) thereby acting as 
a link between periodontal disease, systemic inflammation and associated comorbidities such 
as cardiovascular disease and neurodegeneration. More recently, gingipains have been 
discovered in the brains of Alzheimer’s patients (Dominy et al., 2019). These findings alone 
are strongly suggestive of a possible causative mechanism of neurodisease whereby 
microbial influence interior and exterior to the oral cavity may initiate, drive and/or contribute 
to neurodegeneration. Furthermore, if this bacterium is so intimately involved in 
neurodegenerative diseases (especially in physiological systems exterior to the oral cavity), 
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the use of its inflammagens as biomarkers may provide clinical utility in terms of diagnostic 
and prognostics. 
The question as to whether this microbe or its exclusive proteases can be found in other forms 
of neurodegeneration such as PD is of particular importance, especially to unveil the role of 
P. gingivalis in neurodegeneration and there is any potential for biomarker utility. Furthermore, 
with the belief that this bacterium is persistent in systemic disease, the effects of gingipains 
on clotting cascades and overall fibrin formation require investigation; especially since defects 
in coagulation contribute to the burden of cardiovascular disease and other chronic 
inflammatory conditions (Lowe and Rumley, 2014). There is minimal research regarding the 
effects of these bacterial inflammagens – RgpA and LPS from P. gingivalis – on blood 
coagulation parameters; hence, this study is one of the first that explores such phenomena in 
detail. 
Therefore, the following research questions direct this thesis: 
 Can bacterial membrane inflammagens from P. gingivalis be detected in blood 
samples of the two most common neuro-inflammatory conditions, namely PD and AD? 
 How does inflammagens from P. gingivalis affect blood clotting? 
 
Models used 
Our objectives are to use a clinical model (PD and AD), as well as two laboratory models, 
namely a healthy blood model and a purified fibrinogen model, to detect and study the effects 
of various membrane inflammagens from P. gingivalis.  
Methodology 
Thromboelastography and rheometry are used to investigate changes in clot kinetics, 
viscoelasticity and deformable capabilities. In addition, confocal and scanning electron 
microscopy are utilized to study terminal clot structure, network and load. 
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Our hypothesis  
We hypothesize that RgpA will be detected, for the first time, in PD blood samples using 
immunohistochemistry. Furthermore, the same technique will be applied to AD samples 
thereby identifying RgpA in the blood (not brain tissue) of these patients. 
Furthermore, due to its fibrinogenolytic activity, fibrinogen incubated with RgpA will result in a 
much lower load of fibrin formed when exposed to thrombin. Plasma clot kinetics and formation 
will shift towards a hypocoaguable state when exposed to RgpA while the rheology of clots 
will be less pliable and stiffer. These effects of RgpA will be altered when co-incubated with 
LPS from the same species of bacteria, P. gingivalis.  
 
Considering these hypotheses, the following aims will frame the working order of this thesis: 
Aim 1:  
To identify P. gingivalis’¸ integral virulent protease, RgpA, in PD and AD blood samples. 
Aim 2: 
To determine the effects of RgpA and LPS from P. gingivalis on clot kinetics and rheology 
using a healthy blood model. 
Aim 3 
To determine the effects of RgpA and LPS from P. gingivalis on terminal fibrin formation and 
network structure using a purified fibrinogen model. 
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CHAPTER 2: LITERATURE REVIEW 
 
In this chapter, we review literature that shows a close link between a microbial presence and 
systemic inflammatory conditions. The literature review aims to bring together various points 
of view and research data, suggesting that patients with systemic inflammatory conditions 
(with the focus directed at neuroinflammatory conditions) often have leaky gut (dysbiosis) and 
conditions such as periodontitis, that allow bacteria to enter into the blood circulation, therefore 
directly influencing cells and proteins of the haematological system. These bacteria may then 
shed their membrane inflammagens, and that these inflammagens might indeed play an 
important role in driving systemic inflammation, and in particular abnormal blood clotting – an 
important hallmark of systemic inflammation seen in conditions such as Parkinson’s and 
Alzheimer’s diseases. This chapter is divided into the following sections: 
Microbes and their role in non-communicable diseases:  Here we discuss, in the light of 
how commensal microorganisms become dysregulated and transform into a dysbiotic 
community capable of causing host dyshomeostasis. 
The oral microbiome: The implication of oral microbial populations in periodontal disease, 
and its burden is discussed here. 
Periodontal disease: An introduction into the characterisation and pathology of periodontal 
disease. 
Defects in coagulation in periodontal disease: This section highlights abnormalities 
observed within periodontal disease and 
Overlapping defects of coagulation in neurodegenerative disease: Here we discuss how 
PD and AD exhibit abnormalities in clotting and the general profile is similar to that of 
periodontal clotting. 
The influence of bacterial inflammagens on clotting processes: The role of bacterial 
membrane products on certain parameters of blood clotting is mentioned here. 
Inflammation and associated systemic dyshomeostasis coupled to periodontal 
disease: This section highlights maladaptations in the immune system which prompt systemic 
inflammation and dyshomeostasis in periodontitis.  
Periodontitis and its links with cardiovascular disease: Associations of periodontitis with 
cardiovascular disease is emphasised here, along with experimental evidence aimed at 
elucidating overlapping mechanisms. 
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Periodontitis and its links with neurodegenerative disease: Associations of periodontitis 
with neurodegenerative disease is emphasised here, along with experimental evidence aimed 
at elucidating overlapping mechanisms. 
Chief periodontal pathogen discovered in the brains of Alzheimer’s disease patients: 
Here we discuss recent findings from early 2019 whereby P. gingivalis’ DNA and certain 
virulent factors were found in the brains of Alzheimer’s patients – the source of inspiration for 
this present thesis. 
Porphyromonas gingivalis: An introduction into the chief periodontopathic bacteria 
implicated in periodontitis and its necessity for oral detriment. 
Gingipains – major virulent factors of P. gingivalis: Here we discuss the role and necessity 
of gingipains in pathology. 
Inflammation as a disturbance of coagulation in periodontitis – the possible role of P. 
gingivalis: How periodontal inflammation, induced by P. gingivalis, may contribute to the 
abnormal coagulation observed in periodontal disease. 
The impact of gingipains on the coagulation system: Here we highlight papers that studied 
the effects of gingipains on parameters on clotting, and how these may relate to systemic 
disease. 
Lipopolysaccharide from P. gingivalis: The influence of LPS from P. gingivalis on 
inflammation and coagulation is mentioned here. 
Concluding remarks: Overall, the impact that dysbiotic oral microbes and gingipains 
produced by P. gingivalis have on inflammation and clotting constituents and processes is 
summarised here. 
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2. Microbes and their role in non-communicable disease 
 
The presence of microbes as well as their activity is being implicated in non-communicable 
disease (Ogoina and Onyemelukwe, 2009, Bui et al., 2019, Deleon-Pennell et al., 2013). 
Conventionally, microbes – such as those found within the gut and oral microbiomes – have 
thought to play little or no role in the pathogenesis of chronic, inflammatory, systemic disorders 
including cardiovascular and neurodegenerative disease. However, research conducted in 
recent decades has implicated the existence and functionality of microbial populations in these 
diseased states (Tang et al., 2017, Leishman et al., 2010, Ilievski et al., 2018, Kaur et al., 
2016, Byndloss and Baumler, 2018) such as CVD, AD, PD, type II diabetes mellitus, 
rheumatoid arthritis and anxiety disorders.  Considering that there exist roughly the same 
amount of microbial cells as host cells in the human body (Sender et al., 2016), albeit 
commensal organisms, it seems plausible that a dysregulation of such symbiotic relationships 
can contribute to diseased states. Whilst commensal microbes play an integral role in 
maintaining physiological homeostasis in terms of human physiology, risk factors such as 
genetics, physical inactivity, poor dietary choices and exposure to harmful substances alter 
the normostatic profile of human microbiomes and allow opportunistic microbes – that are 
often present at low, non-pathogenic concentrations – to proliferate to levels that prompt 
microbial dysbiosis and subsequent host dyshomeostasis (DeGruttola et al., 2016). This is 
known to occur in the gut microbiome whereby an increased risk of developing or driving 
T2DM (Sharma and Tripathi, 2019), CVD (Jin et al., 2019) and neurology-related conditions 
(Spielman et al., 2018, Ambrosini et al., 2019), ranging from anxiety disorders to Alzheimer’s 
pathology, is observed. Furthermore, the gut dysbiosis is often accompanied by leaky gut 
characterised by increased permeability of the intestinal epithelia, especially in the context of 
neurodegenerative disorders (Maguire and Maguire, 2019). It has been proposed that bacteria 
are able to traverse the gut wall and enter circulation whereby bacterial inflammagens can 
elicit an immune response and that chronic persistence of this mechanism drives systemic 
inflammation (Kell and Pretorius, 2018).  
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2.1. The oral microbiome 
 
While much focus has been directed at the gut microbiome in the context of NCD, the oral 
microbiome is beginning to receive the attention it deserves. In the past, it was routine to view 
the oral microbiome’s functionality with value only to dentists and orthodontologists. However, 
it soon became apparent that periodontal disorders inflict detriment on not just the oral cavity 
but also systemic physiology (Kim and Amar, 2006). Periodontal disease – characterised by 
soft and dense tissue loss within the oral cavity – is a NCD driven solely by dysbiotic 
(dysregulated) bacterial activity, particularly as a primary aetiological factor (Leishman et al., 
2010). Interestingly, this disorder is strongly associated with CVD (Slocum et al., 2016), AD 
(Singhrao and Olsen, 2019) PD (Chen et al., 2018a). Poor dental hygiene and hence 
periodontal disease exhibits a significant correlation with both of these neurodegenerative 
disorders (Chen et al., 2018a, Schwarz et al., 2006, Singhrao and Olsen, 2018, Chen et al., 
2017a) and cardiovascular disease (Slocum et al., 2016, Sudhakara et al., 2018). These 
significant correlations are suggestive of overlapping microbial activity whereby chief 
pathogens in periodontitis contribute to the pathogenesis of cardiovascular and 
neurodegenerative disease.  
A predominant mechanism of comorbid manifestation includes immune dysregulation caused 
by periodontopathic bacteria (Holmstrup et al., 2017, Velsko et al., 2014, Ilievski et al., 2018, 
Hajishengallis et al., 2015); however, while inflammatory sequela governed from the oral cavity 
is a convincing tie between periodontal disease and CVD, AD and PD, oral pathogens most 
likely operate in a more atopobiotic manner. Atopobiosis, the infection of microbes in atypical 
locations such periodontopathic bacteria in the haematological or central nervous system, 
allows organisms to exert a more direct effect on specific tissues, i.e. pathological influence 
on neurons in the hippocampal region of the brain, thereby contributing more directly to AD 
than simply orchestrating inflammation from the oral cavity. Relevantly, this atopobiotic 
phenomenon in periodontal disease has been supported by the finding that oral pathogens 
enter the haematological system via periodontal lesions (Olsen and Progulske-Fox, 2015, 
Ambrosio et al., 2019, Tomas et al., 2012). Since oral pathogens are noted to enter blood, 
their effects on haematological and cardiovascular constituents are of particular importance. 
As reported by the WHO, in consideration of epidemiology, NCDs are responsible for the 
majority of global mortalities; this emphasizes the need to comprehensively denote possible 
aetiological factors – such as the role of microbes – that contribute to NCD with the aim of 
optimizing preventative and treatment options. Out of the list of NCDs, CVD is responsible for 
an estimated 18 million annual deaths and is therefore regarded as the leading cause of global 
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mortality. An interesting trend observed with cardiovascular disease is its propensity to exist 
as both a primary disease and a comorbidity to other NCDs including PD (Potashkin et al., 
2019), AD (Tublin et al., 2019) and periodontal disease (Leishman et al., 2010, Herzberg, 
2001). This, along with the persistence of CVD as the leading cause of mortality, makes CVD 
the primary mode of death among these chronic inflammatory disorders and beckons for 
investigation into overlapping mechanisms – especially those that pose relevance to 
cardiovascular health such as the functionality of periodontopathic bacteria in coagulation.  
 
2.2. Periodontal disease  
 
Periodontal disease – a chronic inflammatory disorder driven by microbial dysbiosis – 
encompasses the infection, inflammation and destruction of oral structures such as the 
gingiva, periodontal ligament and supporting bone structures. According to the WHO, the 
Global Burden of Disease Study 2016 estimated that nearly half of the world’s population is 
affected by periodontal disorders and therefore is regarded as one of the most common non-
communicable diseases alongside cardiovascular pathologies. On the lower end of the 
severity spectrum is gingivitis, the infection of the gums. While this is reversible, if left 
untreated it is likely that gingivitis will progress into periodontitis (Donley, 2019, Page et al., 
1978). The degradation of connective tissue as a result of periodontal disease is the most 
common cause of tooth loss in adults (Kinane et al., 2017). Periodontitis is routinely diagnosed 
by measuring the sulcus between teeth and gums as well as assessing the propensity for 
bleeding upon probing, the two major hallmarks of this disorder; other relevant parameters 
involved in diagnostics are plaque levels, furcation (loss of bone in root trunk of teeth), gum 
recession and tooth mobility (Preshaw, 2015). Figure 1 shows the prevalence of periodontitis 
among certain age groups in several countries. It is true that the burden of periodontitis 
increases with age. In Figure 1A, the rating of severity of periodontal pathology – called the 
community periodontal index (CPI) – is depicted. Bleeding upon probing as a solitary symptom 
receives a rating of one at the lower end of the scale. Bleeding along with calculus, a form of 
hardened dental plaque is rated 2. At the more severe end of the scale, periodontal pockets 
of 4-5mm and more than 6mm are indicative of a CPI rating of 3 and 4, respectively. These 
stages are considered overt periodontitis. 
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2 (Calculus and bleeding) 
1 (Bleeding on probing) 
0 (No disease) 
A B 
C D 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The prevalence of periodontal disease and severity among different age groups and 
countries using the community periodontal index (CPI). A) Degree of periodontal severity. B) 
Prevalence results among a 15-19 year-old population. C) Prevalence results among a 25-44 
year-old population. D) Prevalence results among a 65-74 year-old population. (Adopted from 
(Nazir, 2017)). 
 
Periodontal disorders are more common in adults where it seems that, over decades, certain 
genes (da Silva et al., 2017, Michalowicz, 1994) and lifestyle factors such as poor dental 
hygiene, diet, minimal exercise and immune dysfunction culminate into oral dyshomeostasis 
which manifests as chronic periodontitis (Tatakis and Kumar, 2005). Interestingly, bacterial 
dysbiosis – which arises as a result of the aforementioned factors – underlies the pathogenesis 
of periodontitis (Sudhakara et al., 2018, Meuric et al., 2017). There exist over 700 known 
species of bacteria in the oral cavity all of which grow in a polymicrobial community of 
commensal biofilms (Aas et al., 2005). Symbiosis between these bacterial communities and 
human cells and tissue is integral for host homeostasis; however, it is when these microbial 
cliques become dysregulated or imbalanced (dysbiosis) that oral dyshomeostasis ensues. 
Dysbiosis allows for pathogenic species and harmful population levels to develop which exerts 
Stellenbosch University https://scholar.sun.ac.za
 14 
 
an implicative effect on the immune system (Levy et al., 2017). Oral dysbiosis in particular 
dysregulates inflammatory markers (Zhang et al., 2019, Abe et al., 2018), causes pathological 
immunomodulation (du Teil Espina et al., 2019, Devine et al., 2015) and degrades host 
gingival and periodontal tissue via direct (proteolytic) and indirect (inflammatory) mechanisms 
(Fouillen et al., 2019, Slocum et al., 2016). Accordingly, periodontal phenotypes present with 
systemic maladaptations of the immune system (Cekici et al., 2014, Leira et al., 2018, 
Hajishengallis, 2015).  It is via these mechanisms – the disruption of host immune function – 
that periodontitis is, in part, believed to contribute to the pathogenesis of comorbidities such 
as neurodegeneration and cardiovascular disease. 
 
2.2. Defective coagulation in periodontal disease  
 
Coagulation is an extremely crucial function in both healthy and diseased states. In healthy 
states, coagulation functions to repair cardiovascular tissue injury in the form of hemostasis. 
While hemostasis still plays an integral role in disease, coagulation processes often exhibit 
maladaptations and defects in kinetics and the efficacy of clot initiation, formation, and 
breakdown (Marshall, 2001). Among CVD deaths, complications in the form of myocardial 
infarctions and strokes remain the predominant implication; more so, coagulation faults are 
present during these events (Undas et al., 2009, Sfredel et al., 2018). Defects in coagulation, 
such hypercoagulability and hypofibrinolysis, stand as a major contributing factor to CVD and 
the manifestation of a cardiovascular event (Lowe and Rumley, 2014, Zhao and Schooling, 
2018). Efficacy of the coagulation system’s activity is therefore an important factor in the 
burden of global mortality. 
Inflammation has a major effect of the clotting system (Bester and Pretorius, 2016, Randeria 
et al., 2019). Relevantly, common to cardiovascular, neurodegenerative and periodontal 
pathology is systemic inflammation (Glurich et al., 2002, Velsko et al., 2014, Tublin et al., 
2019, Fowler et al., 2001) – this overlap between pathophysiological biomarkers in the chronic 
inflammatory diseases in question makes mechanisms of comorbid causation difficult to 
discern. Regardless, dysregulated and zestful inflammatory processes are prominent 
aetiological and driving factors for the pathogenesis of most systemic diseases. In relation to 
the clotting kinetics, an inflammatory state of the haematological phenotype is often associated 
with defective coagulation characterised by hypercoagulation, excessive, rapid clotting, and 
hypofibrinolysis, a reduced clot degradation (Kell and Pretorius, 2015, Bester et al., 2018).  
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Relatively, periodontal disease presents with abnormal coagulation that is often characteristic 
of increased clot propensity (Sato et al., 2003, De Luca et al., 2017, Dikshit, 2015). These 
defects in clots have been associated with an increased risk for thrombosis in periodontal 
disease afflicted patients (Dikshit, 2015, Senini et al., 2019). Implementation of non-surgical 
therapy reduced platelet counts in periodontal patients (Banthia et al., 2013); another study 
demonstrated that similar treatment had favourable effects on markers of the clotting system. 
It has been put forth that periodontal-induced inflammation (as a result of bacterial dysbiosis) 
gives rise to this prothrombotic state (Weickert et al., 2017). Whether the dyshomeostasis in 
the clotting system observed in periodontal disease is directly (inflammagens acting directly 
on clotting machinery) or indirectly (inflammation) caused by periodontopathic pathogens is 
yet to be fully explained. Nonetheless, this prothrombotic state, inspired from dysregulated 
inflammatory cues (Bester and Pretorius, 2016, Randeria et al., 2019, Kell and Pretorius, 
2015), is thus a major risk factor for the occurrence of a cardiovascular event and hence poses 
as an important link between periodontal disorders and (cardiovascular) mortality. 
 
2.3. Overlapping defects of coagulation in neurodegenerative disease 
 
Alzheimer’s and Parkinson’s disease both exhibit abnormalities in clotting processes which 
contributes to an increase in the overall prothrombotic state of these individuals (Maiese, 2015, 
Kalita et al., 2013) – similar to that of periodontal pathology. Hyperactivation of the intrinsic 
clotting pathway is present in neurodegenerative disease (Suidan et al., 2018). It has been 
demonstrated that clotting kinetics and strength in AD patients is impaired due to increased 
clot formation, hyperactivated platelets, increased levels of fibrinogen and decreased 
fibrinolysis (Suidan et al., 2018, Cortes-Canteli et al., 2012, Klohs et al., 2012); furthermore, 
this was also found in AD mice models and these researchers correlated levels of amyloid 
beta – the hallmark molecular defect of this disease – and cognitive defects with biomarkers 
of coagulation. Fibrinogen – the zymogen to the clot constituent fibrin – has been found 
entangled with amyloid beta plaques which leads to aggregates of fibrinolytic-resistant clots 
(Cortes-Canteli et al., 2012), not to mention increased loads of amyloid β deposits. Decreasing 
the levels of fibrinogen in diseased mice relays ameliorative effects on neuropathology 
including lessened blood brain barrier (BBB) permeability, decreased amyloid beta load, 
improved cognitive function and reduced inflammation (Cortes-Canteli et al., 2012). This 
suggests that abnormalities within the coagulation system may root the manifestation of 
certain phenotypes observed within AD, especially in relation to amyloid beta and resultant 
degradation-resistant clots.  
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Abnormal clotting kinetics and cases of thrombosis has also been observed in PD populations 
(Cortes-Canteli et al., 2010). Amyloid formation of fibrin(ogen) in PD plasma has been 
discovered (Pretorius et al., 2018c). Hypercoagubility and hyperactivated platelets contribute 
to the prothrombotic state observed in PD (Adams et al., 2019) – the same phenotype 
observed in periodontal disease. This may contribute to altered hemostasis and fibrin 
formation observed between these disorders. Erythrocytes – once thought to be bystanders 
in terms of coagulation – participate in determining terminal clot architecture and blood flow. 
Eryptotic erythrocytes pose as viable diagnostic and therapeutic biomarkers in PD (Pretorius 
et al., 2014) and likely contribute to impaired blood flow through thrombi. Additionally, 
Parkinsonism drugs impact coagulation and decreases the fibrinolytic capabilities of the 
clotting system (Sato et al., 2003).  
Certain microbes exert a more direct effect on the clotting system. Microbial cells of non-oral 
origin and their molecular products have been found within T2DM, PD and AD clots 
(Armstrong et al., 2013, de Waal et al., 2018). Other bacteria have been known to degrade 
fibrin clots via enzymatic means (Loof et al., 2014). These data indicate that microbes, or at 
least their shed membrane inflammagens, are present and bioactive in the blood system of 
individuals suffering from chronic inflammatory conditions that were once viewed as sterile. 
These findings substantiate a relationship between aberrant coagulation in systemic disease 
and the presence of microbes. It is thus of interest to identify oral pathogens – which show a 
strong relation to inflammatory conditions such as AD, PD and CVD – in the haematological 
system of individuals suffering from systemic disease and assess their impact on coagulation, 
especially as their atopobiotic presence is eminent in overt periodontal disease. Furthermore, 
targeting these periodontopathic bacteria may provide clinical benefit in those disorders that 
exhibit a strong correlation with periodontal disease. 
Ultimately, PD, AD and periodontal disease share similarities in their phenotypic clotting 
profile. Since the potential of microbial contribution to chronic inflammatory disease, 
particularly neurodegeneration and CVD (Figure 2), has been highlighted, and that 
coagulation efficacy is compromised in these disorders, identifying microbes in such disorders 
and understanding their influence on the clotting system is warranted. Relevantly, the oral 
microbiome is under the spotlight because of its correlation with PD, AD and CVD. 
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Figure 2: Intimate association between CVD, neurodegenerative disease and periodontal 
disease which is predominantly driven by dysbiotic bacteria in the oral cavity. 
 
2.4. The influence of bacterial inflammagens on clotting processes 
 
Bacterial products have been implicated in the efficacy of clotting processes (Loof et al., 2014, 
Pretorius et al., 2018b). Fibrinogen – the zymogen of the clot constituent – is a 340kDa 
glycoprotein present within circulation at a concentration of 2-4mg/ml. It is composed of two 
sets of three polypeptide chains, namely Aα, Bβ, and γ. What should be noted is that particular 
variations in the cleavage of these polypeptides during enzymatic conversion to fibrin result in 
a number fibrin variations that constitute clots with some that pose a degree of cardiovascular 
risk (Wolberg, 2016); proteolytic bacteria capable of cleaving fibrinogen may favour the 
production of these particular clots. Two well studied bacterial inflammagens, LPS as well as 
LTA, from gram-negative and gram-positive bacteria respectively, exert an implicative effect 
on clot kinetics and terminal structure. A study conducted by Pretorius et al (2018) 
demonstrated that LPS from Escherichia coli and LTA from various gram-positive bacteria 
altered the biochemical nature of fibrin(ogen) as well as clot kinetics. These bacterial 
endotoxins increased amyloidogenesis – albeit in different manners – of fibrin(ogen) which 
resulted in aberrant fibrin networks. Furthermore, the kinetics of coagulation was altered 
favouring a more hypercoaguable state when samples were exposed to these inflammagens. 
These data emphasize the eminent effect that low-levels (0.4-1 ng.L-1) of bacterial products 
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have on the coagulation system. While it is true that inflammatory responses mediated by LPS 
alters the clotting cascade via platelets and endothelial cells (Dayang et al., 2019), purified 
fibrinogen models exposed to LPS has also shown aberrations in fibrin structure (Pretorius et 
al., 2016) – this implies that LPS interferes with cleavage and processing of fibrinogen and its 
polypeptides into fibrin which is independent of inflammatory cues as platelets and white blood 
cells are absent in a purified fibrinogen model. LPS-binding protein has also been 
demonstrated to reverse or ameliorate defective clotting observed in plasma from Parkinson’s 
individuals (Pretorius et al., 2018c). This indicates that LPS is likely present in the 
haematological system in PD and act as a potential therapeutic target, especially in the context 
of coagulation. Also the alteration of the biochemical nature of fibrin(ogen) in the presence of 
certain inflammagens and in diseased states has been discovered. Amyloid formation of this 
clotting protein pair is induced by inflammation, bacterial products and disease thereby 
resulting in a terminal clot with undesired properties such as resistance to fibrinolysis and 
increased resistance blood flow (Pretorius et al., 2016, Pretorius et al., 2018b, Pretorius et al., 
2018d).   
 
2.5 Inflammation and associated systemic dyshomeostasis coupled to periodontal 
disease 
 
Inflammation is important in the context of coagulation as it exerts profound effects on the 
state of clotting – it can induce a hypercoagulability in the proinflammatory state (Bester and 
Pretorius, 2016). Hence, it is important to detail the inflammatory component of periodontitis 
in order to tie relations to abnormal coagulation observed in oral pathologies as well as 
associated comorbid diseases such as PD and AD, both of which show overlapping 
characteristics in clotting defects. As mentioned, the detriment induced by periodontal 
disorders is not limited to the oral cavity. Periodontitis has an intimate correlation to a cohort 
of systemic diseases including CVD (Levy et al., 2017, Stewart and West, 2016), rheumatoid 
arthritis (Bingham and Moni, 2013, Rodriguez-Lozano et al., 2019), T2DM (Chee et al., 2013), 
respiratory infections (Saini et al., 2010, Bansal et al., 2013), AD (Teixeira et al., 2017, 
Singhrao and Olsen, 2018, Chen et al., 2017a) and PD (Chen et al., 2018a, Kaur et al., 2016, 
Chen et al., 2017b). These associations thereby infer a possible link between the microbes 
that orchestrate chronic periodontitis and systemic dyshomeostasis. Chronic inflammation is 
a major commonality among systemic diseases (Straub and Schradin, 2016, Kaur et al., 2016) 
and stands as a strong target of therapy to ameliorate a primary condition as well as prevent 
the manifestation of comorbidities (Gonzalez-Gay et al., 2014, Newcombe et al., 2018, Ursum 
et al., 2013). As a chronic inflammatory disease, periodontitis is likely associated with CVD, 
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AD and PD due to reasons related to the immune system and inflammation (Holmstrup et al., 
2017, Chistiakov et al., 2016, Torrungruang et al., 2018, Kaur et al., 2016, Hajishengallis, 
2015). 
Periodontal pathogens are inflammophilic (Hajishengallis, 2014); a chronic inflammatory state 
is thus ideal for the infection of these microbes. The phenotype of periodontitis presents with 
upregulated inflammatory markers such as interleukin (IL) 1β, IL-6, IL-12, IL-17, IL-23, 
interferon-γ, vascular endothelial growth factor, C-reactive protein (CRP), tumour-necrosis 
factor (TNF) α and serum amyloid A (Leira et al., 2018, Zekeridou et al., 2019, Kalburgi et al., 
2014, Singh et al., 2014, Hirai et al., 2019).  These markers are common to other chronic 
inflammatory disorders such as CVD, AD and PD (Ramos et al., 2009, Watanabe et al., 2016, 
Luan and Yao, 2018). These overlapping inflammatory cues are suggestive of the possibility 
that immune-related matters are in part responsible for the link between periodontitis and the 
aforementioned diseases. 
Both the innate and adaptive immune system are implicated during the pathogenesis of 
periodontitis (Cekici et al., 2014). In the initial stages of periodontal disease, predominantly 
gingivitis, the immune response to relevant pathogens in the oral cavity is a defensive one. In 
these early stages, subgingival plaque can be resolved and homeostasis can be returned – 
this immune response is not necessarily pathological. However, it is when these microbial 
communities and periodontal lesions persist that defects in immune regulation occur. While 
the first line of defense, components of the innate immune system, is the first to become 
dysfunctional in periodontitis, it is a combination of maladaptations in both the innate and 
acquired immune system that drives pathology. 
Acute inflammation observed in the early stages of periodontal disease is governed by the 
innate immune system, whose components – typically the complement system and toll-like 
receptors (TLRs) present on phagocytes and other cells (Hajishengallis et al., 2015) (Daniel 
and Van Dyke, 1996)  – are impaired. There are also physical defense barriers in the oral 
cavity such as tight intercellular junctions that prevent bacteria and their molecular by-products 
from entering tissue. However, during periodontal pathology, these epithelial cells become 
inflicted by pathogens and this mucosal barrier becomes ‘leaky’ thereby allowing bacteraemia 
to ensue (Chen et al., 2019). Systemic bacteraemia induced by periodontal pathogens leads 
to persistent activation of inflammatory processes (Hirschfeld and Kawai, 2015) – this could 
be a possible link between periodontal disease and cardiovascular and neurodegenerative 
disease.  
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The complement system is a group of humoral and cell-associated proteins apart of the innate 
immune system responsible for maintain microbial homeostasis. Bacterial evasion of the 
complement system is eminent in periodontitis and leads to chronic and maladaptive 
functioning of the immune system (Hajishengallis, 2015). Components of this system are 
degraded by bacterial proteases which lead in ineffective clearance its targets (Popadiak et 
al., 2007). In the complement system, there are generally three modes of activation – the 
classical pathway, the lectin pathway and the alternative pathway – all of which result in 
bacterial cell destruction in a similar manner. The classical pathway is stimulated by 
immunoglobulins which ultimately lyse bacterial cells via the membrane attack complex 
composed of the terminal complement proteins, C6 and C9. The lectin pathway converges 
with the classical pathway at the activation of C3, an integral convertase of the system; prior 
to this commonality, mannose-binding lectin targets carbohydrates present on the surface of 
microbial cells which subsequently interacts with complement proteins required to activate C3. 
The alternative pathway – which is significantly activated during periodontal disease (Cekici 
et al., 2014) – is stimulated by bacterial inflammagens such as lipopolysaccharide (LPS). 
While antibodies, utilized in the classical pathway, against periodontal pathogens are 
widespread in periodontal disease, the alternative pathway still predominates complement 
activity in this disorder; this may be due to the fact that oral bacterial products have the ability 
to cleave immunoglobulins thereby nullifying pathway activation (Vincents et al., 2011).  
The involvement of the complement system in periodontal inflammation seems to be 
significant. In a rat model of periodontitis, a C5a receptor antagonist was used which resulted 
in a significant decrease in periodontal inflammation and bone loss (Hajishengallis et al., 
2015), thereby demonstrating that complement functioning is an important factor in disease 
progression. In comparison to C5a and its receptor, C3 is common to all three complement 
pathways. The activity of C3 is therefore is independent of the mode of complement activation; 
this makes C3 a favoured therapeutic target (in the context of the complement system). In 
experiments using non-human primates, a C3 inhibitor significantly prevented inflammation 
and tissue destruction (Maekawa et al., 2014a). To quantitatively express the reduction in 
inflammation brought about by the C3 inhibitor, researchers measured levels of TNF, IL-1β, 
and IL-17 – all inflammatory biomarkers were lowered in the presence of the inhibitor. This 
study offers valuable insight into the complement system’s role in periodontal disease. In a 
disease as immunologically complex as periodontitis, it is therapeutically useful to identify such 
impactful biomarkers such as C3. Furthermore, C3 activity is known to modulate toll-like 
receptor (TLR) signalling, typically in a positive manner (Hajishengallis and Lambris, 2010). 
Thus, the inhibition of C3 may also help to reduce periodontal and thus systemic inflammation 
mediated by TLR signalling. Ultimately, components of the complement system – specifically 
Stellenbosch University https://scholar.sun.ac.za
 21 
 
C3 and C5a receptor – exhibits crosstalk with TLRs which leads to leukocyte mobilisation and 
further inflammation, all of which contributes to gingival and bone degradation (Hajishengallis 
et al., 2019) 
TLRs are a group of receptors apart of the immune system that acts to recognize pathogen-
related markers, formally termed pathogen-associated molecular patterns (PAMPs). These 
receptors recognize bacterial LPS, and other pathogen markers such as LTA, which results in 
a cascade of immune-related reactions that orchestrate inflammation in the context of both 
innate and adaptive immunity. Periodontitis is governed by uncontrolled, pathogenic bacterial 
populations; hence, the levels of PAMPs are high which increases TLR signalling thereby 
leading to further inflammation. Interestingly,  TLR2 and TLR4, the two forms of the receptor 
most notably compromised in periodontal disease, have been proposed as reliable diagnostic 
markers for periodontal disease (Ilango et al., 2016).Dendritic cells, lymphocytes, 
macrophages and epithelial cells all possess these receptors, and are implicated in 
periodontal pathology (Ilango et al., 2016). When this receptor is activated by respective 
agonists, a stream of intracellular processes occur which ultimately results in cytokine, 
chemokine and antimicrobial peptide synthesis and secretion (Schaefer et al., 2004). These 
inflammatory markers become dysregulated and contribute to systemic inflammation – 
another link between oral dysbiosis and systemic disease. Osteoclast precursors also express 
TLRs; modulation of this particular receptor by periodontal pathogens lead to increased 
osteoclast activity and thus increased bone resorption (Hienz et al., 2015) – a characteristic 
pathophysiological factor of periodontitis. Ultimately, activated TLRs in a periodontal context 
is largely responsible for excessive production of inflammatory molecules (Parthiban and 
Mahendra, 2015), those which drive periodontal pathology. TLRs prompt both innate and 
acquired immune system processes and therefore pose as a reasonable target for the 
reducing systemic inflammation.  
Neutrophils also play an important role in the progression of periodontal disease. These white 
blood cells are actually the most common type found within periodontal lesions (Hajishengallis 
and Hajishengallis, 2014) thereby emphasizing their importance in combating microbial 
activity in the oral cavity. Individuals with congenital defects in neutrophil function and 
recruitment exhibit an increased risk of IL-17-driven bone loss (Moutsopoulos et al., 2014). 
However, with that being said, it has also been shown that levels of neutrophils in periodontal 
regions also correlate with the severity of periodontitis (Landzberg et al., 2015). This is 
indicative of the possibility that neutrophil functioning becomes dysregulated. Relevantly, 
neutrophils have been shown to contribute to local, harmful tissue inflammation and 
degradation in periodontal lesions (Ryder, 2010). It has been suggested that pathogens are 
able to evade their defence mechanisms (Hajishengallis, 2015). With relation to the 
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complement system and TLRs, interference from oral pathogens lowers the phagocytic 
capabilities of neutrophils (Maekawa et al., 2014b); this bacterial evasion of neutrophils 
requires direct crosstalk between complement factors, specifically C5a receptor, and TLRs 
which are present on relevant cell types. Although their ability to digest bacteria is hindered, 
neutrophils are still functional in the sense that they contribute to inflammation via cytokine 
and chemokine production – this leads to constant leukocyte recruitment to infected areas. 
Additionally, to aid the transmigration of neutrophils through tissues, connective tissue is 
degraded (Maekawa et al., 2014b). In the context of periodontal lesions, these neutrophil 
implications aggravate tissue loss. The dysregulation of this immune consortium – consisting 
of complement system, TLRs, phagocytes – certainly contributes to chronic, systemic 
inflammation and thus may be largely responsible for correlations made between periodontitis, 
cardiovascular and neurodegenerative pathologies. 
If the primary innate response is insufficient to remove the microbial threat, pathogenic 
antigens will be presented to cellular components of adaptive immunity, T and B lymphocytes. 
Dendritic cells, macrophages and other lymphocytes act as antigen-presenting cells informing 
B and T cells of their respective target’s molecular makeup. B cells are responsible for 
producing immunoglobulins which exist on the membrane of these lymphocytes or as soluble 
antibodies which are secreted by active B-cells called plasma cells (Hoffman et al., 2016). 
These processes form part of humoral immunity. Contrastingly, T-cells govern cell-mediated 
adaptive immunity. The role of T-cell adaptive immunity and related cytokine functioning plays 
an important role in the manifestation of periodontitis (Silva et al., 2015). A type of T cell, T-
helper 17, is known to be very active and largely responsible for the excessive IL-17 and IL-
23 levels observed in periodontitis (Ohyama et al., 2009). Tissue destruction, such as that of 
gingival and bone degradation, is prompted by elevated levels of IL-17 (Shabgah et al., 2014). 
Knockout studies have provided insight into the extent of T cell involvement in periodontitis. 
Immunodeficient strains of mice have shown that T cell deletion results in reduced periodontal 
pathology, specifically reduced bone loss (Baker et al., 2002). Furthermore, T cells express a 
degree of crosstalk with osteoclasts and their precursors, and their osteoclastogenic role has 
been denoted (Weitzmann et al., 2001). They increase levels of receptor activator of nuclear 
factor-κβ ligand (RANKL) which acts as an agonist for osteoclastogenesis (Chen et al., 2014). 
The need for T cells for pathological bone loss and their ability to promote osteoclastogenesis 
highlights their involvement in periodontitis. This impactful role of T cells makes them a useful 
therapeutic target in relation to bone loss in periodontal disease.  
It seems that a complex aberration of immune function, both from the innate and acquired 
compartments, is integral for periodontal pathogenesis. After all, periodontal pathogens are 
inflammophilic. It is intuition to thus assume that the influence of pathogenic microbes on 
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immune function in periodontitis is in part responsible for the manifestation of comorbidities. 
This emphasises the need, in order to fully treat a patient and account for possible 
comorbidities, to join disciplines in the context of oral health care professionals and general 
practitioners and associated specialists. An interdisciplinary approach to this pathological 
complexity has already been stipulated (Lyons and Darby, 2017) in order to reduce associated 
comorbidities such as CVD and neurodegeneration. 
 
2.6. Periodontitis and its links with cardiovascular disease 
 
For decades correlations between periodontal disease and CVD have been made. In the late 
1980s Mattila et al. (1989) completed a study that evaluated the state of dental health in 
patients that have suffered a myocardial infarction. The researchers demonstrated that dental 
health was seemingly worse in the patients suffering from cardiovascular complications than 
healthy controls. Using 9760 participants, a study followed individuals for fourteen years in 
order to learn the risk of developing coronary artery disease (CAD) in healthy and periodontal 
disease inflicted individuals. Among the participants, those with periodontitis showed an 
overall increased risk for total mortality and a 25% increase in the risk of developing CAD 
(DeStefano et al., 1993). More noteworthy is the finding that among men aged 50 and younger, 
those with periodontitis exhibited a staggering 72% increase in the risk of developing CAD 
than the controls. The National Health and Nutrition Examination Survey (NHANES III) 
provided invaluable data relevant to periodontal comorbidities. Out of 5564 subjects assessed 
for cardiovascular health, the extent of periodontal pathology was linked to an odds ratio of 
3.8 [95% CI (1.5–9.7)] in relation to periodontally healthy subjects (Arbes et al., 1999); this 
was after adjustment for confounding factors including smoking, diabetes mellitus, blood 
pressure, age, sex and gender. Late in the 1990s, when the association between periodontitis 
and CVD was disclosed, researchers correlated levels of subgingival bacteria – those 
implicated in periodontitis – with the risk of experiencing a heart attack (Stein, 1999). 
In a meta-analysis of nine cohort studies, periodontitis was 19% more likely to be associated 
with a cardiovascular event such as a stroke or myocardial infarction (Janket et al., 2003). 
Once again, the degree of association was dependent on age. Individuals afflicted with 
periodontal disease that were under the age of sixty-five exhibited an increased risk of 44% 
as opposed to the total population’s risk of 19%. Another comprehensive meta-analysis study 
completed in 2009 concluded a total risk for developing CVD estimated at 34% (Blaizot et al., 
2009). The link between oral health and CVD, by this point, was more than convincing to 
negate it as coincidence. Interventional and causal studies provided more conclusive 
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inferences thus paving way for further investigation into the intimacy between periodontitis and 
CVD, two chronic inflammatory conditions.  
In 2010, de Oliveira et al. (2010) investigated if routines of tooth brushing had a significant 
outcome on inflammation as measured by CRP levels, fibrinogen levels and cardiovascular 
health. Participants that reported poor dental hygiene exhibited an elevated risk of developing 
CVD and also presented with higher serum CRP and fibrinogen levels. As CRP and fibrinogen 
are acute-phase reactants whose levels increase during acute-phase responses 
(inflammatory cue), this study is suggestive of increased inflammation as a result of poor 
dental health. Although parameters of coagulation were not measured, an increase in 
fibrinogen levels is also indicative of a hypercoaguable state (Kattula et al., 2017). The 
concentration of serum CRP levels are positively correlated with the severity of periodontal 
disease (Podzimek et al., 2015). Furthermore, elevated CRP levels are deemed a major risk 
factor for the development of CVD (Fonseca and Izar, 2016). It would therefore provide some 
benefit to decrease CRP levels in periodontitis in order to prevent cardiovascular 
complications. In an intervention study, CRP levels, as well as another acute-phase reactant 
called haptoglobin , were decreased in patients with periodontitis by intervening with dental 
scaling, root planning and drug administration (flurbiprofen) (Ebersole et al., 1997). However, 
whether the ameliorative effects observed in this study were due to dental care is blurred by 
the presence of flurbiprofen, a non-steroidal anti-inflammatory drug. In another study, 120 
patients with periodontitis were subjected to nonsurgical periodontal treatment and had their 
CRP levels measured 45 days after the first day of intervention; the results from this particular 
study concluded that dental treatment alone significantly reduces CRP levels (Kumar et al., 
2013). In a diabetic population with poor oral health, periodontal treatment lowered the rate of 
CVD (Peng et al., 2017). Common to most assessments is the fact that periodontal 
intervention favours cardiovascular health. This establishes an intimate link between the two 
disorders and hence requires further attention. 
Even with this data in hand, clinically targeting certain inflammatory markers such as CRP in 
periodontitis with the aim of preventing CVD has provided minimal benefit (Li et al., 2017, 
Offenbacher et al., 2009). Nonetheless, these studies in question favour correlation as 
opposed to causation; and the correlations made between oral health and CVD are significant 
enough to prompt action. This beckons for more comprehensive investigation – apart from 
overlapping inflammatory profiles – into the detailed pathogenesis of periodontitis – 
particularly the activity of periodontal pathogens – and how it may promote cardiovascular 
complications.  
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Relevantly, there are two prominent theories as to how periodontitis is causally linked with 
CVD (Hajishengallis, 2015). The first stipulates that periodontal lesions act as a gateway for 
oral pathogens to enter circulation and induce bacteraemia through systemic dissemination. 
This ideology is supported by the fact that bacteraemia is well documented in periodontal 
patients (Horliana et al., 2014, Silver et al., 1977, Tomas et al., 2012). These atopobiotic 
bacteria then contribute to further systemic inflammation and possibly act in an atherogenic 
manner. The next theory is infers that key microbes implicated in periodontitis are able to 
induce dysbiosis in the gut which subsequently causes systemic inflammation leading to CVD. 
This theory was supported by a mice model in which oral pathogens induced endotoxemia 
and systemic inflammation (Arimatsu et al., 2014); however, the intervening pathogens were 
undetectable in the gut thereby raising scepticism regarding the exact mechanism in question. 
Overall, cardiovascular health is eminently related to oral health; the next step is to determine 
the functionality of periodontal microbes in the cardiovascular system. 
 
2.7. Periodontitis and its links with neurodegenerative disease 
 
For several years now neurodegenerative disease has been correlatively tied to periodontal 
disorders (Cicciu, 2016, Ranjan et al., 2018, Rai et al., 2012). In the context of neuropathology, 
the focus here is directed on PD and AD – the two most common neurodegenerative disorders. 
While these two neurodegenerative diseases differ in molecular hallmarks and clinical 
symptoms, disease aetiology and pathophysiological mechanisms are somewhat similar (Xie 
et al., 2014). Neuroinflammation is an integral factor to the development and progression of 
these pathologies (Guzman-Martinez et al., 2019). Along with inflammation in the central 
nervous system (CNS), AD and PD also presents with a systemic inflammatory phenotype 
(Ferrari and Tarelli, 2011, Chiang et al., 2017) with a noted dysregulation of inflammatory 
biomarkers (Adams et al., 2019). In addition to the fact that periodontal disease has a 
pronounced inflammatory impact and is capable of leisurely causing systemic inflammation, 
periodontitis also manipulates the immune system in a manner that upregulates 
neuroinflammation (Teixeira et al., 2017). Focusing on driving factor of periodontal disease, 
oral pathogens are believed to – as with CVD – be at the root of this comorbidity between 
periodontitis and neurodegeneration. Proposed mechanisms of operation are (i) persistent 
bacteraemia; (ii) atopobiosis of oral pathogens into the CNS via the trigeminal nerve; and (iii) 
orchestration of pathological activity from the oral cavity, i.e. production of toxins and 
inflammatory molecules that enter the blood and/or nervous system (Teixeira et al., 2017). 
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In 2008, researchers sought to compare cognitive function among periodontally healthy and 
ill elderly individuals; their results reflect a similar trend with those of studies assessing links 
with CVD – cognitive defects (disease) is positively associated with periodontal disease (Yu 
and Kuo, 2008). After this period in time, a research branch designated to the implication of 
periodontal disease in neurodegeneration was well established. In recent years it was shown 
that individuals practicing regular dental hygiene exhibited less of a chance of developing PD 
(Chen et al., 2018a) – this is synonymous to dental hygiene and cardiovascular disease. 
Another study correlated the severity and duration of PD with oral pathology (van Stiphout et 
al., 2018). Ultimately, these data supports the notion that having periodontitis is associated 
with an increased risk of developing PD (Chen et al., 2017b, Kaur et al., 2016). The ability of 
periodontal disease to causes neuro- and systemic inflammation has lead researchers to 
propose oral pathology as ‘the missing link’ of Parkinson’s pathogenesis (Kaur et al., 2016). 
However, whether systemic inflammation caused by oral pathogens is orchestrated solely 
from the oral cavity or whether they disseminate systemically and impose a nearer and more 
direct effect on the CNS and in PD is yet to be fully discerned. In fact, periodontopathic bacteria 
have not yet been identified in the CNS nor the blood of individuals afflicted with PD. 
AD too has a significant relation to periodontal pathologies (Poole et al., 2015, Singhrao and 
Olsen, 2018, Chen et al., 2017a, Poole et al., 2013). AD and periodontitis share common 
inflammatory cytokines – typically IL-6 and TNF α (Cestari et al., 2016). This highlights the 
possibility of overlapping mechanisms accredited to inflammation (Bui et al., 2019). This notion 
is strongly supported (Teixeira et al., 2017, Ganesh et al., 2017, Singhrao and Olsen, 2019). 
Even with this data in hand, immune (dys)function is extremely complex and thus exact 
mechanisms are difficult to recognize. It is known that inflammatory reasons, accredited to 
pathogens, account in part for the association between periodontal, AD and PD; however, the 
identification of these oral pathogens or products in the CNS – at the scene of neuropathology 
– was lacking.  
Poole et al. (2013) sought to identify periodontopathic bacteria, specifically their molecular 
trace, in brain tissue of Alzheimer’s patients post-mortem. They were one of the first to 
demonstrate that LPS from chief periodontopathic bacteria is present in the AD brains (Poole 
et al., 2013). This finding fed the notion that virulent factors from oral pathogens can leave the 
oral cavity and infect other systems such as the brain. Even more so, LPS stimulates 
neuroinflammation, amyloid beta aggregation and causes cognitive impairment (Sheng et al., 
2003, Zhao et al., 2019) – these factors, along with the finding of oral-derived LPS in AD 
brains, makes the contribution of periodontopathic bacteria in neurodegenerative disease 
convincing. The identification of atopobiotic pathogens and their products became a more 
convincing tie between oral health and neurodegeneration then speculation over inflammation. 
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Further studies were propelled in this direction. Mice studies have revealed the translocation 
and presence of periodontopathic bacteria in the brain (Poole et al., 2015, Ishida et al., 2017) 
and immunoglobulin analysis in human patients suffering from AD have found antibodies 
against oral pathogens (Laugisch et al., 2018, Sparks Stein et al., 2012). All of this data is 
greatly significant and support a tight relation between periodontitis and neurodegeneration, 
but it was only in 2019 that a breakthrough happened. 
 
2.8. Chief periodontal pathogen discovered in the brains of Alzheimer’s disease 
patients 
 
There exist many species of pathogenic bacteria implicated in periodontal disease which may 
be expected to link with systemic pathology, but only a few are capable of prompting 
periodontitis in solitude. Stealing the spotlight from hundreds of other bacterial species, a 
complex of three bacteria – the red complex – is highlighted as the most implicative bacterial 
species and consortium in periodontitis (Socransky et al., 1998). The red complex comprises 
the species Bacteroides forsythus, Treponema denticola, and Porphyromonas gingivalis, with 
P. gingivalis being the most pathogenic of the trio (Mysak et al., 2014). It is predominantly the 
interplay of activities between these anaerobic bacteria that coordinate the induction of a 
dysbiotic polymicrobial profile capable of wreaking oral tissue detriment. With that being said, 
an emphasis is laid on the activity of P. gingivalis as this bacterium,  apart from the fact that 
this anaerobe can single-handedly promote and drive systemic inflammation and periodontitis 
(Blasco-Baque et al., 2017, Bui et al., 2019), is the most implicated in systemic disease 
(Singhrao and Olsen, 2019) This study will thus focus on P. gingivalis. 
While many associations have been made between periodontitis and other chronic 
inflammatory disorders such as cardiovascular and neurodegenerative pathology, there are 
very few that have directly identified the chief periodontal pathogen – P. gingivalis – in an 
atopobiotic manner such as in the brain or blood. However, to much avail, this scarcity was 
contested in 2019.  P. gingivalis and its molecular signatures were recently discovered in the 
brains of individuals with overt AD (Dominy et al., 2019). Dominy et al. (2019) demonstrated 
the presence of DNA and virulent proteases originating from P. gingivalis in the cerebral cortex 
of Alzheimer’s patients thereby directly implicating this bacterium at the scene of 
neuropathology; to take it even further, these researchers correlated the levels of these 
exclusive proteases with ubiquitin and tau pathology (Dominy et al., 2019). In a mouse model 
apart of the same study, oral P. gingivalis translocated to the brain where an increase in 
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amyloid β 1-42 was observed. When a gingipain-inhibitor was used as a therapeutic 
intervention, a reduction in neurotoxicity was eminent and therefore suggests that gingipains 
may be a significant contributor to neurodegeneration.  
This is the most direct connection between this bacterium, periodontitis and 
neurodegeneration. While Parkinson’s and Alzheimer’s are individualised pathologies, the 
development of neurodegeneration is believed to share causative and driving factors; hence, 
it is fair to hypothesize that P. gingivalis will be identified in haematological tissue of both PD 
and AD patients. Prospective identification of this oral pathogen in PD, coupled to the recent 
discovery of P. gingivalis in AD brains, may provide further insight into the pathogenesis of not 
only PD but neurodegeneration as a whole. Along with a study that discovered P. gingivalis in 
organs, particularly brain and atherosclerotic tissue, exterior to the oral cavity in mice (Velsko 
et al., 2014), this bacterium is now suspected to travel and persist in the haematological 
system. Hence, the influence that this chief periodontopathic bacterium and its virulent factors 
have on coagulation – since clotting processes are impaired in both periodontal and 
neurodegenerative disease – is of particular importance and thus requires further 
comprehensive investigation. 
 
2.9. Porphyromonas gingivalis 
 
P. gingivalis is a gram-negative, non-motile, rod-shaped anaerobic bacterium that is infamous 
for its pathogenic potential in the oral cavity. This bacterium acts as a keystone pathogen in 
the context of periodontal disorders by causing bacterial dysbiosis in the oral cavity, 
manipulating immune function and thus orchestrating the pathogenesis of periodontitis 
(Darveau et al., 2012). Whilst P. gingivalis is present and homeostatically maintained in 
healthy states, it has the capacity to act opportunistically and induce the transformation of 
balanced microbiota into a pathogenic (dysbiotic) community (keystone pathogen). The 
severity of periodontitis exhibits a positive correlation to bacterial load (Lee et al., 2015, Ready 
et al., 2008). As periodontitis has been shown to associate with a number of systemic 
diseases, it is believed that P. gingivalis – the chief initiator and driver of periodontitis – has a 
prominent role to play in associated inflammation and the pathophysiology of comorbidities. 
Multiple studies have investigated and discovered possible roles played by this bacterium and 
its virulent factors in a list of diseases including cardiovascular pathologies (Yun et al., 2005, 
Zhang et al., 2015, Sheets et al., 2005, Sheets et al., 2006, Mougeot et al., 2017, Hussain et 
al., 2015, Brodala et al., 2005, Liccardo et al., 2019, Patrakka et al., 2019, Velsko et al., 2014), 
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neurodegeneration (Singhrao et al., 2017, Dominy et al., 2019, Poole et al., 2015, Poole et al., 
2013, Kaur et al., 2016, Singhrao and Olsen, 2018), diabetes (Liccardo et al., 2019, Makiura 
et al., 2008, Ohtsu et al., 2019), rheumatoid arthritis (Jung et al., 2017, Okada et al., 2013, 
Mikuls et al., 2014) and cancer (Zhou and Luo, 2019). Hence, treatment options for 
periodontitis mostly work to reduce the activity and thus success of P. gingivalis (Puth et al., 
2019, Kugaji et al., 2019, Sha and Garib, 2019) with the hope of reducing further bone loss 
and soft tissue damage as well as preventing systemic inflammation and the onset of 
comorbidities.  
Eminent to the pathological potential of this prokaryote, P. gingivalis possesses an extensive 
inventory of virulent factors. Table 1 list the main virulent factors of P. gingivalis and briefly 
mentions their role in pathology. To sum up, P. gingivalis uses these endogenous molecules 
to enable survival and persistence by manipulating and evading the host immune system 
(Hajishengallis, 2011, Olsen et al., 2016, Slocum et al., 2016), altering host proteins via 
cleavage and citrullination (Engstrom et al., 2018, Marchant et al., 2013, Guo et al., 2010),  
inducing apoptosis of host cells (Desta and Graves, 2007, Inaba et al., 2018) and aiding in the 
survival and success of other pathogenic microbes (Karkowska-Kuleta et al., 2018, Olsen et 
al., 2017). Although all these virulent factors act in unison to cause dyshomeostasis, there are 
specific enzymes – called gingipains – that take credit for the majority of the pathological 
success of P. gingivalis (Zenobia and Hajishengallis, 2015) and thus constitute the focus of 
this study.  
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Table 1: Important virulent factors produced by P. gingivalis that enable its pathological 
success in human tissue.  
Virulent Factors Action and consequences       References 
Gingipains Degradation of host antimicrobial peptides, 
immunoglobulins and central complement 
component C3; prevents complement activation; 
nutrient acquisition via proteolysis; causes tissue 
damage and subsequent inflammation 
(Popadiak et al., 
2007, Grenier, 
1992, Palm et al., 
2013) 
Peptidylarginine 
deiminase 
Host and bacterial protein citrullination linked to 
arthritis; induction of autoantibodies in rheumatoid 
arthritis 
(Maresz et al., 
2013, Wegner et 
al., 2010) 
FimA fimbriae Binds CXCR4 and induces CXCR4-TLR2 crosstalk; 
cAMP signalling and inhibition of nitric oxide-
dependent killing; required for oral colonization and 
infection gingival epithelial cells 
(Hajishengallis et 
al., 2008, 
Hajishengallis and 
Lambris, 2011) 
SerB (serine 
phosphatase) 
Suppresses IL-8 production by dephosphorylation 
of NF-kB p65; prevents nuclear translocation and 
transcription 
(Takeuchi et al., 
2013) 
Adapted from (Zenobia and Hajishengallis, 2015) 
2.9.1. Gingipains – Major virulent factors of P. gingivalis 
 
P. gingivalis is incapable of carbohydrate cleavage (asaccharolytic) and instead relies on 
proteolysis for the accession of nutrients (Lamont and Jenkinson, 1998). This beckons for the 
production and utility of proteolytic enzymes. Accordingly, P. gingivalis has evolved to 
synthesize trypsin-like proteases called gingipains that confer functionality meeting and 
extending past the need for nutrients. 
Gingipains are cysteine proteases produced by P. gingivalis that account for roughly 85% of 
the proteolytic activity of this bacterium (Li and Collyer, 2011). There exist three forms: 
arginine-specific gingipain A (RgpA), arginine-specific gingipain B and lysine-specific 
gingipains (Kgp). These proteases are named according to their respective cleavage site e.g. 
Kgp cleaves at lysine-Xaa residues and Rgp at arginine-Xaa residues. These enzymes exist 
in monomeric forms (e.g. RgpA) or may be processed into a non-covalent protease complex 
such as the RgpA-Kgp complex. These enzymes are present on the membrane of this species, 
released extracellularly in a soluble form and also contained in outer membrane vesicles (Imai 
et al., 2005, Veith et al., 2014). As trypsin-like proteases, gingipains enable P. gingivalis to 
carry out life-sustaining activities which include adherence to host substrates such as 
fibrinogen, fibronectin, haemoglobin, laminin and erythrocytes (Pike et al., 1996, Belstrom et 
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al., 2011), degrading host proteins (Potempa et al., 2003) such as plasma proteins, 
extracellular matrix proteins, cytokines and proteins involved in the complement system 
thereby leading to immune manipulation and evasion (Abdi et al., 2017, Mezyk-Kopec et al., 
2005, Slocum et al., 2016, Hajishengallis, 2011), causing agglutination and haemolysis of 
erythrocytes (Li and Collyer, 2011, Shah and Gharbia, 1989) and heme acquisition for 
auxotrophic reasons (Smalley et al., 2011, Lewis, 2010). Studies involving immunisation, 
knock-outs and inhibitors of gingipains demonstrate the necessity of these enzymes in the 
initiation and progression of periodontal pathologies (Table 2). As the fate of this bacterium’s 
success is considerably determined by the functionality of these gingipains, the detection and 
inhibition of gingipains may be a vital key in combating its virulence and role in periodontal 
and systemic pathology. 
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Table 2: Previous experimental results demonstrating the necessity of gingipains for the 
pathological success of P. gingivalis. The studies referenced are limited to periodontal 
disease; the reason being is that P. gingivalis originates from the oral cavity and hence the 
pathological activity of gingipains precedes systemic infection. Furthermore, the discovery of 
P. gingivalis in physiological systems exterior to the oral cavity is scarce.  
Mode of 
Experiment 
 
Model Utilized 
 
Result 
 
References 
Immunization with 
RgpA  
Murine periodontitis 
model 
Prevention of P. 
gingivalis-induced oral 
bone loss 
(Gibson and Genco, 
2001) 
Immunization with a 
peptide domain of 
Rgp 
Murine subcutaneous 
chamber 
model 
Immunity against P. 
gingivalis infection 
(Genco et al., 1998) 
Immunization with 
RgpA-Kgp complex 
Murine skin abscess 
model 
Immunity against P. 
gingivalis infection 
(O'Brien-Simpson et 
al., 2000) 
Immunization with 
the RgpA-Kgp 
proteinase-adhesin 
complex 
 
Rat periodontitis 
model 
Resistance to P. 
gingivalis colonization 
and 
periodontal bone loss 
 
(Rajapakse et al., 
2002) 
Immunization with 
wild type P. 
gingivalis 
gingipain-deficient 
mutants and re-
infection 
Murine skin abscess 
model 
Protection against re-
infection elicited by the 
wild-type strains 
devoid of gingipains 
(Yoneda et al., 2003) 
Inoculation of P. 
gingivalis W50 with 
Rgp-specific 
inhibitor 
Murine subcutaneous 
chamber 
model 
  
Inactivation of Rgp 
attenuates virulence 
(Genco et al., 1999) 
Passive 
immunization of 
human subjects  
 
Anti-gingipain 
antibodies were 
applied into 
periodontal pockets 
Treated group had 
reduced level of P. 
gingivalis and 
decreased bleeding on 
probing 
(Yokoyama et al., 
2007) 
 
Since the invasion of the haematological and other systems by P. gingivalis is distinguished, 
and considering it is associated with increased cardiovascular risk (Ghizoni et al., 2012), the 
effect of its integral proteases on coagulation (specifically fibrinogen to fibrin conversion) 
Stellenbosch University https://scholar.sun.ac.za
 33 
 
warrants further investigation. Additionally, inflammation brought about by P. gingivalis may 
also cause defective clotting. 
 
2.9.2. Inflammation as a disturbance of coagulation in periodontitis – the possible role 
of P. gingivalis 
 
As a defence mechanism, the human body allows inflammation to occur in order to identify 
harmful entities such as foreign substances and organisms, as well as to repair damaged 
tissue. Simply, there exist two types of inflammation: acute and chronic inflammation. Acute 
inflammation functions to remove organisms, toxins and repair acute injuries in a short period 
of time. Maladaptations in this operation may lead to dysregulated inflammatory cues that 
persist and lead to chronic inflammation. Chronic inflammation occurs over a long period of 
time and results from long-term exposure or failure to remove necessary organisms, toxins or 
endogenous molecules, autoimmune implications, and recurring episodes of acute 
inflammation (Pahwa and Jialal, 2019). Chronic inflammation is causative of pathological 
detriment and subsequent systemic disease (Straub and Schradin, 2016). Systemic disease 
encompasses disorders such as diabetes mellitus type II, neurodegeneration (Alzheimer’s and 
Parkinson’s disease), psoriasis, rheumatoid arthritis, cancers, systemic lupus erythematosus 
and periodontitis, all of which presents with a chronic inflammatory profile (Multhoff et al., 
2011, Tsalamandris et al., 2019, Lotti et al., 2010, Munoz et al., 2010, Cekici et al., 2014). 
Interestingly, bacterial endotoxins have been implicated in these disorders (Gomes et al., 
2017, Romani et al., 2013, Pretorius et al., 2017a, Jain et al., 2019). 
Intimately related to chronic inflammation are aberrations in normal coagulative processes 
(Levi and van der Poll, 2010). The clotting system comprises of platelets, coagulation 
machinery (enzymes, cofactors) that enables functionality and obviously fibrinogen. Platelet 
function is considerably influenced by inflammation, especially in the chronic state (Senturk, 
2010). Inflammatory markers such as cytokines are dysregulated during (chronic) 
inflammation and can modulate platelet receptors thereby causing platelet hyperactivity 
(Randeria et al., 2019) – a contributing factor to hypercoagubility. Bacterial endotoxins have 
also been implicated in the functionality of these clotting entities (Lopes Pires et al., 2017, 
Saluk-Juszczak et al., 2000). During (chronic) inflammation and an acute phase response, 
fibrinogen (an acute phase reactant) levels increase (over 7mg/ml) and act as a prominent 
cardiovascular risk factor (Fibrinogen Studies et al., 2005). The concentration of this plasma 
protein is a determinative factor for clotting efficiency; hence, increased levels of fibrinogen 
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leads to increased clot formation – a relation that leads to hypercoagubility and an increased 
risk for thrombosis.  
A significant modulator of coagulation is inflammation (Foley and Conway, 2016). 
Inflammatory processes in periodontal disease contributes to excessive bleeding observed in 
gingival tissue (Dikshit, 2015). Oral pathogens greatly modulate immune function in order to 
ensure their survival and subsequent pathogenesis of pathology including periodontitis, 
atherosclerosis and Alzheimer’s disease (Olsen et al., 2016). Predominantly, periodontopathic 
bacteria operate to evade immune function thereby leading to their persistence in the oral 
cavity. However, with that being said, the overall inflammatory response is not nullified but 
instead becomes dysregulated and pathological in function (Hajishengallis, 2011). Thus, this 
immune-modulation by oral pathogens starts off as an evasion strategy that inevitably results 
in pathological systemic inflammation characterised by cytokine dysregulation (Hajishengallis, 
2015). This influence on systemic inflammation mediated by oral bacteria may underlie 
aberrant coagulation and downstream effects seen in periodontitis and associated 
comorbidities. 
In the context of a more specific influence on the clotting system, gingipains exert more of a 
direct effect by targeting key role players in the coagulation system, predominantly 
fibrin(ogen). 
 
2.9.3. The impact of gingipains on the coagulation system 
 
Excessive bleeding of the gums – one of the hallmarks of periodontal pathology – is 
encouraged by gingipains (Imamura et al., 1995). Furthermore, patients with gingivitis or 
periodontitis exhibit increased levels of plasma proteins in salivary fluids, an indication of 
plasma leakage due to increased vascular permeability (Henskens et al., 1993). These 
proteases possess the ability to process proteins involved in the clotting cascade as well as 
modulate the activity and concentration of platelets in the blood (Benedyk et al., 2016). One 
prominent effect of gingipains on the clotting system is the ability to cleave fibrinogen and fibrin 
(Imamura et al., 1995). Hence, this presents with major implications for the efficacy of 
coagulation and terminal clot properties.  
Results from experiments involving human plasma and exogenous RgpA has unveiled the 
ability of this specific gingipain to activate prekallikrein with ensuing increases in the levels of 
bradykinin, an inflammatory mediator that promotes vascular permeability enhancement 
(Imamura et al., 1994). Imamura et al (1994) speculated that this activation of the 
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kallikrein/kinin is a direct cause for the increase in gingival crevicular fluid (an inflammatory 
exudate) seen in periodontal disorders. The same researchers, whom have provided 
comprehensive insights into gingipains and their role in the coagulation system, also 
demonstrated RgpA-mediated activation of a number of clotting factors. Both RgpA and RgpB 
activate factor X in a dose- and time-dependent manner (Imamura et al., 1997); this coincides 
with lower prothrombin times measured in the same experiment. This suggests that Rgp-
dependent factor X activation seems to promote faster clotting cascades (hypercoagulation). 
Rgps also activate factor IX (Imamura et al., 2001b) and prothrombin (Imamura et al., 2001a). 
Both the activation of factor IX and X leads to increases in thrombin – a factor which regulates 
the activation of other coagulation factors, catalyses the conversion of fibrinogen to fibrin and 
activates protein C (anticoagulant) when bound to thrombomodulin (Esmon, 2001). Increases 
in thrombin increase fibrin formation and results in densely arranged clots (Wolberg and 
Campbell, 2008), factors which can contribute to abnormalities in coagulation and subsequent 
cardiovascular implications (Kim et al., 2016, Kell and Pretorius, 2015). 
Platelets are also manipulated by gingipains (Pham et al., 2002). In a mice model, researchers 
inoculated subjects with gingipains and observed a successive increase in both platelet activity 
and count (Benedyk et al., 2016). Gingipains act proteolytically on protease-activated 
receptors 1 & 4 on the membranes of platelets; this results in an intracellular influx of calcium 
ions and subsequent platelet aggregation comparable to that of thrombin (Lourbakos et al., 
2001). Klarström Engström et al (2014) determined that Rgp is essential for the activation of 
platelets (Klarstrom Engstrom et al., 2015). Interestingly, the sensitivity of human platelets to 
epinephrine, an agonist of platelet activity (Shattil et al., 1989), is increased in the presence of 
RgpA (Nylander et al., 2008); there is speculation as to whether this may be a link between 
stress and cardiovascular disease.   
Fibrinogen – the zymogen to fibrin, the structural constituent of clots – exerts significant 
binding affinity towards all three gingipains (Pike et al., 1996). It is speculated that this assists 
in attachment and adhesion to host surfaces as do gingipains with fibronectin, an extracellular 
matrix protein (Pike et al., 1996). In addition to simply binding fibrinogen, gingipains have 
fibrin(ogen)olytic potential (Imamura et al., 1995). Whilst the trio of gingipain enzymes degrade 
the α chain of fibrinogen synonymously, RgpA is more efficient in cleaving the β chain – a 
phenomenon attributed to differences in amino acid residues in the active site of the proteases 
(Ally et al., 2003). Degradation of fibrinogen decreases clot formation and will diminish the 
ability of the coagulation system to resolve bleeding. Consequently, it seems likely that 
gingipain-mediated fibrinogenolysis underlies the hallmark symptoms of excessive bleeding 
and inflammation observed in periodontal tissue.  
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Clinical significance of this fibrin(ogen)olytic capability may not be limited to periodontal 
disorders; additionally, the role of gingipains on systemic physiology and more specifically 
overall coagulation may pose of benefit to chronic inflammatory patients whom of which may 
present with simultaneous periodontitis. This ideology is supported by recent findings of 
gingipains in the hippocampal region of the brain of Alzheimer’s patients (Dominy et al., 2019) 
as well as in human atherosclerotic tissue (Kozarov et al., 2005). 
Even though the fibrinogen-degrading role of gingipains has been elucidated, a holistic 
approach using an array of modern techniques such as thromboelastography, rheometry, 
scanning electron microscopy and confocal microscopy will offer a better understanding of 
these proteases’ effect on the kinetics of coagulation, the deformation and response of clots 
under shear force and the architecture of terminal fibrin networks. The presence of this 
microbe in diseased states also requires establishment, especially since their existence has 
been found in cardiovascular and neurological disease. 
 
2.9.4. Lipopolysaccharide from P. gingivalis 
 
LPSs are immunogenic membrane components of gram-negative bacteria. While there are 
intra- and inter-species differences between LPSs in terms of structure, function and 
serogenicity, common to this class of bacterial products is the prominent immune response 
they induce (Pulendran et al., 2001, Tan and Kagan, 2014). With relevance to the oral cavity, 
LPS PG (LPS from P. gingivalis) has been shown to increase the production of inflammatory 
cytokines including such as interleukin (IL)-1, IL-6, IL-8 and TNF-α from gingival cells (Imatani 
et al., 2001, Taguchi et al., 2015). Fibroblasts of the periodontal ligament have been noted to 
succumb to oxidative stress induced by LPS PG (Golz et al., 2014) and release inflammatory 
cytokines via TLR signalling (Wang and Ohura, 2002, Savitri et al., 2015), the major detection 
and signalling receptors of the innate immune system mentioned earlier. Through such 
immune-related means, inflammatory cytokines produced by LPS PG may contribute to an 
overall state of systemic inflammation common to periodontitis, CVD, AD and PD (Singhrao 
and Olsen, 2019, Deleon-Pennell et al., 2013).  
Focusing on neurodegeneration, LPS PG favours serum amyloid beta peptide formation (Leira 
et al., 2019). This mechanism likely contributes to amyloid load in neuropathology and 
therefore the severity of AD (Lee et al., 2019). Using mice, TLRs have also been implicated in 
LPS PG-induced cognitive impairment, inflammatory cytokine dysfunction and 
neuroinflammation (Zhang et al., 2018). Comprehensively, it has also been shown that LPS 
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PG, with the involvement of cathepsin B, can in solitude cause AD-like phenotypes in mice 
(Wu et al., 2017b). It should be noted that LPS from other bacterial species are also capable 
of giving rise to an AD phenotype in mice (Zhan et al., 2018). Nonetheless, it is expected that 
LPS PG, due to its immunogenic capabilities, are important virulent factors used by P. 
gingivalis to cause systemic inflammation and thus dyshomeostasis. 
In the context of coagulation, there is little research investigating the function of LPS PG in 
clotting processes. Studies conducted using other species’ LPS have all provided similar 
results – that LPS causes increased clotting propensity (hypercoaguable state) and 
anomalous fibrin network formation (Pretorius et al., 2016, Pretorius et al., 2018b, 
Pernerstorfer et al., 1999).  From the one study that does assess LPS PG, it was shown that 
LPS PG causes platelet activation via the Cdc42 receptor which causes platelet spreading 
and pseudopodia formation (Senini et al., 2019) – modulation of platelet activity via periodontal 
pathogens may be in part  responsible for the prothrombotic phenotype observed in 
periodontitis. It would be expected that LPS PG prompts a similar response to other forms of 
LPS. What is of particular importance, in relation to proteolytic functionality in clotting, is the 
association of LPS with gingipains. These two inflammagens form a complex that is virulently 
functional (Takii et al., 2005); subsequently, the activity of gingipains while bound to LPS PG 
was noted to be altered. The researchers involved discovered that the LPS-gingipain complex 
inhibited the inflammatory response characteristic to LPS. This phenomenon has been 
postulated as one of P. gingivalis’ potential immune evasive techniques (Takii et al., 2005). 
Furthermore, the proteolytic activity in the complex form deviated significantly from gingipains 
that were in their free (monomeric) form. In the frame of coagulation, this complex form can 
alter the outcome of the overall effect that gingipains impose on clot formation. As P. gingivalis 
exists by utilizing both LPS and gingipains, the co-incubation of these two bacterial 
inflammagens in experiments is warranted. Hence when assessing the role of gingipains in 
clotting experiments, co-incubation with LPS PG will offer considerable insight as both 
bacterial inflammagens are present in the physiological state. Such an intervention will help 
understand the impact that LPS PG in the presence of gingipains or the LPS-gingipain 
complex has on clot kinetics and fibrin formation. 
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2.10. Concluding remarks 
 
Figure 3 depicts the hypothesized order of events beginning from oral dysbiosis to systemic 
inflammation and coagulation dysfunction.  The influence of P. gingivalis on systemic health 
and disease is currently under scrutiny, especially after the study conducted by Dominy and 
colleagues (Dominy et al., 2019). As this bacterium has recently been found in Alzheimer’s 
disease brains, atherosclerotic plaques and thrombi from stroke patients, the persistence and 
activity of this bacterium in the haematological system may be pose as a major link between 
periodontitis and systemic disease. Since cardiovascular disease – a comorbidity of 
periodontal and neurodegenerative disease (Firoz et al., 2015, Vogelgsang et al., 2018) – is 
the leading cause of global mortality and that defects in coagulation contribute significantly to 
this burden, the role that gingipains from P. gingivalis has on the coagulation cascade and 
overall fibrin synthesis warrants investigation.  
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Figure 3: The sequence of events leading from oral dysbiosis, governed by P. gingivalis, to 
systemic inflammation and subsequent aberrations in the coagulation system. Typically, oral 
dysbiosis contributes significantly to inflammation. Ultimately, dysregulated immune function 
manifests as systemic inflammation. This proinflammatory state, along with gingipains from P. 
gingivalis, alters normal functioning of the coagulation system which results in impaired clot 
kinetics, formation and degradation. 
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Following this comprehensive literature review, the following chapters will further investigate 
the influence of gingipains and LPS of P. gingivalis on the haematological system, and also 
determine if it is indeed present in the circulation of PD and AD patients. For a quick recap, 
our research questions and hypotheses are again presented: 
Research questions: 
 Can bacterial membrane inflammagens from P. gingivalis be detected in blood 
samples of the two most common neuro-inflammatory conditions, namely PD and AD? 
 How does inflammagens from P. gingivalis affect blood clotting? 
Our hypothesis  
We hypothesize that RgpA will be detected, for the first time, in PD blood samples using 
immunohistochemistry. Furthermore, the same technique will be applied to AD samples 
thereby identifying RgpA in the blood (not brain tissue) of these patients for the first time. 
Furthermore, due to its fibrinogenolytic activity, fibrinogen incubated with RgpA will result in a 
much lower load of fibrin formed when exposed to thrombin. Plasma clot kinetics and formation 
will shift towards a hypocoaguable state when exposed to RgpA while the rheology of clots 
will be less pliable and stiffer. These effects of RgpA will be altered when co-incubated with 
LPS from the same species of bacteria, P. gingivalis.  
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CHAPTER 3: STUDY DESIGN AND SAMPLE COLLECTION  
 
The present study takes the form of a cross-sectional study design conducted at the 
Department of Physiological Sciences within the Clinical Hemorheology and Coagulation 
Research Group. 
3.1. Ethical Statement 
 
Ethical clearance was obtained from the Health Research Ethics Committee (HREC) of 
Stellenbosch University (South Africa) (approval number HREC Reference #: N19/03/043) 
(Appendix A). Written informed consent was obtained following a verbal explanation of the 
study details and perusal of the written consent forms (Appendix B). Study participants 
received a unique number that was used to guarantee discretion by protecting their identity. 
Furthermore, researchers followed Good Clinical Practice and abided by ethical codes of 
conduct throughout this study. With that being said, the guidelines of the Declaration of 
Helsinki were abided by. 
3.2. Study Population and Blood Collection  
 
3.2.1. Control Samples 
 
Forty-two healthy volunteers were recruited from the general population residing in 
Stellenbosch, Cape Town and surrounding areas. In this control population, 26 were female 
and 17 were male. Exclusion criteria for the control population included (i) inflammatory and/or 
coagulation disease (ii) infection (iii) smoking (iv) conflicting medication such as aspirin or 
hormone replacement drugs that may affect blood clotting processes. Blood was drawn in 
sodium citrate tubes by a registered medical biological scientist (Health Professions Council 
of South Africa (HPCSA)) and phlebotomist (MW: 0010782) from the Department of 
Physiological Sciences, Stellenbosch University.  
3.2.2. Parkinson’s Disease Samples 
 
The PD samples were collected from n=40 patients visiting and receiving treatment at 
Tygerberg hospital in Bellville, Cape Town. The PD patients were n=15 female and n=25 male. 
PD volunteers were recruited with the following inclusion criteria: (i) a confirmed diagnosis by 
a neurologist of which includes the use of the Unified Parkinson’s Disease Rating Scale 
(UPDRS), as well as the Hoehn and Yahr scale used to rate the relative level of the PD 
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disability, (ii) males and females of any age, (iii) devoid of any anticoagulant medication. 
Participants who were unable to provide written consent were excluded from this study. 
3.2.3. Alzheimer’s disease Samples (Obtained during 2015) 
 
Ethical clearance was obtained from the Faculty of Health Science Research Committee of 
the University of Pretoria (Appendix C). Exclusion criteria included smoking, infectious 
disease, pregnancy, hormonal therapy and comorbid disease (vascular dementia). 
Alzheimer’s disease patients were diagnosed and treated by a neurologist that took caution to 
offer blood samples from those without vascular dementia. These patients were subjected to 
the Mini-Mental State Exam which is used to rate the severity of cognitive dysfunction. Blood 
collection was carried out in the same manner as previously stated – collected in citrate tubes.  
3.3. Storage of Plasma Samples  
 
After the blood withdrawal, the samples viable for coagulation testing were allowed to rest for 
30 minutes at room temperature after which they were centrifuged at 3000g for 10 minutes. 
The plasma was then carefully collected with a Pasteur pipette and transferred into a 1.5mL 
microcentrifuge tube for storage at -80°C. When samples were required for testing, the sample 
tubes were allowed to thaw at room temperature. 
5.4. Statistical Analysis 
 
Statistical analyses performed in this study were conducted on GraphPad Pad (7.04). Shapiro-
Wilk normality tests were performed on all data in order to determine whether parametric or 
nonparametric tests were done. Normally distributed data was then analysed with paired T-
tests whereas nonparametric data underwent Mann-Whitney-Wilcoxon tests. Significance of 
results were determined at p < 0.05. Mean grey value of confocal images was measured on 
ImageJ 1.45s. 
 
5.5. Demographics of the subject populations  
The ages of healthy, PD and AD groups were subjected to a Shapiro-Wilk normality test of 
which the data passed as normally distributed. The age data is represented in Table 3 and 
visually depicted in Figure 4. The mean ages are 62, 68 and 73 for the healthy, PD and AD 
population, respectively. Hoehn and Yahr ratings of PD patients are also represented in Table 
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3, alongside the respective patient’s age. Hoehn and Yahr ratings are used to classify the 
stages and severity of PD.  
Table 3: The ages of all study participants plus the Hoehn and Yahr rating for each PD patient. 
Control 
(40) PD (40) AD (10) 
    
Hoehn & 
Yahr   
69 58 2 76 
72 69 2 65 
61 53 2 68 
79 68 3 79 
49 59 2 86 
50 66 3 81 
77 59 2 82 
81 59 3 58 
74 59 2 59 
74 69 2 78 
77 68 3 mean = 73 
72 75 2,5   
76 64 2,5   
66 65 1   
69 64 1   
66 66 4   
84 64 1   
72 63 2,5   
71 64 4   
39 72 3   
57 87 2   
59 70 2   
53 62 3   
59 71 4   
55 64 1,5   
47 63 3   
50 77 2   
51 71 1   
49 73 2   
51 87 3   
57 72 5   
56 65 2   
54 81 2,5   
50 52 1   
56 60 2,5   
58 72 1   
58 79 2,5   
Stellenbosch University https://scholar.sun.ac.za
 44 
 
58 83 2   
49 59 1   
57 84 3   
mean = 62 mean = 68     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Box plots of the age differences among the healthy, PD and AD populations 
participating in this study.  
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Layout of the rest of the thesis 
 
This study is further subdivided into three research chapters according to the type of model 
applied, namely:  
 Chapter 4: clinical blood model in which AD and PD blood samples will be probed 
for the presence of RgpA;  
 Chapter 5: healthy blood model in which the effects of recombinant RgpA on clotting 
kinetics and rheology will be tested on healthy whole-blood (WB) and platelet-poor 
plasma (PPP) samples; and  
 Chapter 6: purified fibrinogen model in which the proteolytic effect of RgpA on 
terminal fibrin network structure will be analysed. 
 
The last few chapters will discuss and conclude the results and issue relevant to this thesis: 
 
 Chapter 7: Discussion of the experimental data obtained in this thesis with relevance 
to overall topic; and 
 Chapter 8: Conclusion, bringing together the clinical relevance of this research 
thesis. 
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CHAPTER 4: CLINICAL STUDY 
4. The detection of RgpA in the blood of PD and AD patients 
4.1. Introduction 
 
With the mounting evidence indicating a strong association of PD and AD with periodontitis, 
and with the recent discovery of DNA and gingipains from P. gingivalis in the brains of patients 
suffering from AD, this section seeks to identify RgpA in PD and AD blood. Here, we use PPP 
from n=40 PD individuals, n=10 AD individuals, and n=40 healthy controls whereby each 
sample is incubated with a fluorescent antibody specific for RgpA; after sample preparation is 
complete, confocal microscopy is used to detect – via fluorescent means – the presence of 
RgpA in a particular sample. The fluorescent intensity of each micrograph, although easily 
discernible via qualitative means, is also measured in a quantitative manner to enhance 
significance.  
The research question we aim to address, by using immunohistochemistry and confocal 
microscopy, is: ‘Can bacterial membrane inflammagens from P. gingivalis be detected in 
blood samples of the two most common neuro-inflammatory conditions, namely PD 
and AD?’  
4.2. Techniques 
 
4.2.1. Immunohistochemistry and confocal microscopy 
 
Immunohistochemistry is the utilization of antibodies for identifying target molecules 
(antigens); normally these are coupled to a fluorophore whose emission can be detected when 
excited. Confocal microscopy is an optimal imaging technique that, in this case, uses 
fluorescence to study target molecules and is a central tool with admirable resolution. For 
instance, in blood and purified fibrinogen models, our research group has detected the 
presence of amyloid, using probes (conjugated to a fluorophore) specific for amyloid character, 
within clots exposed to bacterial LPS and LTA (Pretorius et al., 2018b). Immunohistochemistry 
in this manner has been implemented to identify bacterial inflammagens, such as LPS (de 
Waal et al., 2018). Together, immunohistochemistry and confocal microscopy will be used to 
identify RgpA in PD and AD blood samples. 
Here, the Zeiss LSM 780 confocal laser scanning microscope (Carl Zeiss Microscope, Munich, 
Germany) was used to view fluorescent signal. 
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4.3. Methods and materials 
4.3.1 Immunohistochemistry and confocal microscopy 
 
In order to detect the presence of RgpA in of healthy, PD and AD individuals, a rabbit 
polyclonal (derived from multiple B-cell lineages) antibody against RgpA, conjugated to 
fluorescein isothiocyanate (FITC), was purchased from Abbexa (catalogue number: 
abx107767). During the preparation, the antibody as well as goat serum was kept on ice. 5μL 
of PPP (PD) or WB (AD) was carefully pipetted onto a microscope slide and left to stand for 2 
minutes. Thrombin solubilized in PBS containing 0.2% human serum albumin with a 
concentration of 20 U·mL-1 was obtained from the South African National Blood Service. 2,5μL 
of thrombin was pipetted directly into the centre of the sample on the microscope slide and 
carefully spread with the pipette tip in order to ensure fibrin network formation. After the 
addition of thrombin, the sample was left for five minutes to allow fibrin fibres and network to 
form and adhere to the slide. The sample was then fixed with 10% neutral buffered formalin 
for 10 minutes. After washing the sample three times with PBS (pH=7.4), a blocking step using 
5% goat serum (diluted with PBS) was employed for five minutes. The sample was then 
incubated with the RgpA FITC polyclonal antibody at a ratio of 1:100 (diluted in PBS) for an 
hour in a dark room. After antibody incubation, the samples were then washed with PBS to rid 
of unbound antibody. A drop of Dako fluorescent mounting media was added and the sample 
was subsequently mounted with a coverslip for confocal imaging. The prepared samples were 
viewed on a Zeiss LSM 780 with ELYRA PS1 confocal microscope using a Plan-Apochromat 
63x/1.4 Oil DIC objective. The gingipain R1 FITC antibody was excited at 488 nm, with 
emission measured at 508 to 570 nm. As a positive control, recombinant RgpA (Abcam; 
catalogue number: ab225982) was added at a final concentration of 500 ng.L-1 to healthy PPP 
(devoid of signal when naïve) and left to rest for 30 minutes; then, this sample was incubated 
with the antibody and visualized to confirm specificity for RgpA.  
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4.4. Results 
4.4.1. Positive control using the polyclonal RgpA antibody 
 
In order to determine the specificity and reliability of binding between the RgpA polyclonal 
antibody and its target in plasma, a positive control experiment was performed (Figure 5). A 
healthy control whose plasma was devoid of fluorescent signal when incubated with the 
antibody received an exogenous dose of 500ng.L-1 recombinant RgpA. Following this addition 
of extrinsic RgpA, the antibody was then added to the plasma in a 1:100 concentration and 
viewed under confocal microscopy. The confocal image in Figure 5A is that of unstained 
plasma with the purpose of negating autofluorescence that may give rise to false positive 
results. When stained with the RgpA polyclonal antibody (Figure 5B), there was no signal 
detected indicating that this plasma sample is lacking a noticeable load of endogenous RgpA. 
Conversely, when exogenous RgpA is added to the plasma and probed with the antibody 
(Figure 5C), definitive signal was obtained. This infers that the antibody has bound to the 
added RgpA thereby ensuring the detection specificity for RgpA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
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Figure 5: Positive control using the RgpA antibody in plasma samples. In this figure, a naïve 
(A) and RgpA antibody-stained (B) depiction of control 9 reflects no fluorescent signal, thereby 
negating the presence or detection of RgpA. Conversely, when control 9 is incubated with an 
exogenous load of recombinant RgpA (500ng.L-1) and then stained with the antibody in 
question, noticeable fluorescence is observed (C-F). This serves to show that the specificity 
of the antibody is restricted to RgpA in plasma samples, and therefore detected fluorescence 
can be attributed to the presence of RgpA. 
 
4.4.2. RgpA in Parkinson’s disease plasma 
 
Figure 6 shows – for the first time – the presence of RgpA in the haematological system of 
Parkinson’s disease patients. Unstained control and PD plasma clots display undetectable 
fluorescent signal (A & C); these micrographs serve to discount autofluorescence that may 
lead to false positive results. When the control samples were stained with the antibody specific 
for RgpA (B), the micrographs yielded imperceptible fluorescent signal therefore 
demonstrating the absence of RgpA in healthy individuals. Conversely, the stained 
Parkinson’s disease clots exhibited extensive fluorescent signal (D-F). This infers, via 
immunohistochemistry, that RgpA, the protease from the chief periodontopathic bacterium P. 
gingivalis, is present in the haematological system of individuals suffering with Parkinson’s 
disease. In order to quantitatively support the observed difference between the control and 
PD populations, the mean grey value (fluorescent intensity) of the confocal images were 
calculated (Figure 7). The Parkinson’s population exhibited a mean fluorescence three times 
that of the controls. Accordingly, a p-value less than 0.001 (****) was determined. This is the 
first evidence to demonstrate the presence of P. gingivalis in the form of its molecular 
signatures in the haematological system of individuals suffering from Parkinson’s disease. 
E F 
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Figure 6: Confocal micrographs of control and Parkinson’s disease plasma clots stained with 
the polyclonal FITC-conjugated gingipain R1 antibody. Control plasma clots, devoid of stain 
(A), shows no fluorescent signal and thus dismisses any presence of autofluorescence which 
may produce false positive results. The same control same is stained with the antibody (B) 
which subsequently lacks fluorescent signal, thereby indicating that the control is devoid of 
the protease. For the Parkinson’s disease plasma clots, unstained samples were also viewed 
to account for any autofluoresence of which none was found (C). Conversely, stained 
Parkinson’s disease clots exhibited significant fluorescence which indicates the presence of 
RgpA in the blood system of these diseased patients (D-H). C & D represents plasma of the 
same individual; D-H are different Parkinson’s disease individuals.  
E F 
G H 
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Figure 7: The difference in mean fluorescent intensity of confocal micrographs between 
healthy and PD plasma stained with the RgpA antibody. This measured fluorescent intensity 
between the two populations, as inferred the mean grey value, supports what is qualitatively 
expressed in Figure 9 – this quantitative measurement supports a significance difference (p < 
0.0001) with the PD population yielding three times the fluorescent signal than the control 
group. (**** = p < 0.0001). Three repeats (micrographs) of each sample were measured to 
increase statistical power. Due to the fact that measurements of the confocal images in 
question record signal intensity in areas rich or absent in RgpA (large deviations), standard 
deviation is negated from the graphs. Significance was established at a p < 0.05. (**** = p < 
0.0001) 
 
4.4.3. Probing for RgpA in Alzheimer’s disease whole blood 
 
Control and Alzheimer’s WB used to make RgpA antibody-stained clots are represented in 
Figure 8. In terms of fluorescence observed, the control samples demonstrated little to none 
(A-B) which highlights the absence or scarcity of RgpA in this population. One control subject, 
however, demonstrated strong fluorescent signal; while this individual may not be have 
Alzheimer’s, it is possible that this subject may have periodontal disease and thus P. gingivalis 
infection. In comparison, the Alzheimer’s population demonstrates considerable qualitative 
fluorescent signal (C-D) indicating the presence of a protease from P. gingivalis. This observed 
difference is quantitatively supported by the measurement of signal intensities (Figure 9) which 
yields a significant difference among the two groups (p < 0.0001). The Alzheimer’s population, 
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albeit only ten subjects, is thus positively associated with the existence of virulent factors from 
P. gingivalis in their blood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Confocal images of WB from healthy and Alzheimer’s disease individuals after 
incubation with the RgpA polyclonal antibody at an exposure concentration of 1:100. A-B) As 
A B 
 
C 
E F 
D 
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a whole, control WB expressed little or no fluorescence. However, one subject in particular did 
demonstrate excessive signal. Alzheimer’s WB samples (C-F) collectively show strong 
fluorescent signal when viewed.  
 
 
 
 
 
 
 
 
 
 
Figure 9: The mean fluorescent intensity between healthy and PD plasma exposed to the 
RgpA antibody. Quantitatively, the mean of signal intensity (E) supports a significant difference 
between the control (x̄ = 0.139) and the Alzheimer’s (x̄ = 0.716) population (**** = p < 0.0001). 
Three repeats (micrographs) of each sample were measured to increase statistical power. 
Due to the fact that measurements of the confocal images in question record signal intensity 
in areas rich or absent in RgpA (large deviations), standard deviation is negated from the 
graphs. Significance was established at a p < 0.05. 
 
 
 
 
 
 
 
 
 
Stellenbosch University https://scholar.sun.ac.za
 55 
 
4.5. Discussion 
 
4.5.1. The detection of RgpA in the haematological system of PD and AD patients 
 
There have been numerous studies depicting that poor oral hygiene and the presence of 
periodontopathic bacteria are major risk factors for the manifestation of these inflammatory 
conditions (Mattila et al., 1989, DeStefano et al., 1993, Schwarz et al., 2006, Tomas et al., 
2012) and in terms of PD and AD, correlations with P. gingivalis are plentiful (Holmstrup et al., 
2017, Chen et al., 2018a, Kaur et al., 2016, Sparks Stein et al., 2012, Singhrao and Olsen, 
2018, Ranjan et al., 2018). Before the study in hand, this bacterium was yet to be discovered 
in physiological systems exterior to the oral cavity in PD patients. Recently, P. gingivalis and 
gingipains were discovered in the hippocampus of AD brains (Dominy et al., 2019). This is a 
significant link between periodontal disease and AD substantiating the associations made 
between the two disorders. The researchers also correlated the levels of gingipains to tau and 
ubiquitin pathology. Also highlighted is that the Dominy et al. (2019) study indicates that the 
atopobiosis of P. gingivalis is eminent, which predominantly occurs through entry into the 
blood and subsequent dissemination (Imamura et al., 2001b, Ambrosio et al., 2019, Horliana 
et al., 2014, Deshpande et al., 1998). This finding by Dominy et al (2019) led to this thesis’ 
first hypothesis that suggests gingipains are present and persistent in the haematological 
system of PD as well as AD patients. Hence, the first aim of this study was to detect RgpA in 
the haematological system of individuals suffering from neurodegenerative disease, 
particularly PD and AD. 
Accordingly, this study is the first to detect the presence of RgpA from P. gingivalis in the 
haematological system of PD and AD populations. Furthermore, it is the first study to show 
inflammagens from P. gingivalis present in an atopobiotic manner in PD patients – in the blood 
as opposed to the oral cavity. Using immunohistochemistry and confocal microscopy, both the 
PD and AD yielded a significant difference (p < 0.0001) in fluorescent intensities when 
compared to controls. Even without quantitative data, this difference was easily discerned in 
a qualitative manner. This finding corroborates the numerous associations of P. gingivalis and 
periodontitis with neurodegenerative disease. Here, we add more support to the theory that 
P. gingivalis is ‘the missing link’ between PD and periodontitis (Kaur et al., 2016). In an 
applicative manner, the significant difference between the presence of RgpA in PD and AD 
patients and healthy controls suggests that this particular gingipain possesses biomarker 
potential – perhaps as a diagnostic (or prognostic) biomarker. Nonetheless, more research is 
required to fully understand the role that this protease plays in PD and AD and how it can be 
utilized clinically. Ultimately, this finding of RgpA in the blood provides novel insight for the 
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pathogenesis, prevention, diagnosis, assessment and treatment of PD and AD, as well as 
other neurodegenerative disorders. 
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CHAPTER 5: HEALTHY BLOOD MODEL 
5. The effects of bacterial inflammagens from P. gingivalis on coagulation kinetics 
and clot rheology 
5.1. Introduction 
 
Since P. gingivalis seems to be significantly implicated in inflammatory conditions as 
demonstrated by recent research, the effect that this bacterium’s virulent factors may have on 
the coagulation system is of interest. After all, increased cardiovascular comorbidities are 
observed in most inflammatory conditions such as PD, AD, periodontal disease and T2DM, 
and defective coagulation – present in these disorders – is a contributing cardiovascular risk 
factor. Although the fibrinogenolytic effect of RgpA is noted, there remains the need to assess 
the effect of this protease, by using modern techniques, on different stages of coagulation, 
such as clot initiation time and stiffness. Hence, a holistic approach using 
thromboelastography and rheometry will offer more insight into the effects of bacterial 
inflammagens from P. gingivalis on certain parameters of coagulation. 
In this chapter, by using thromboelastography and rheometry, the research question we aim 
to address here is: ‘How does inflammagens from P. gingivalis affect blood clotting?’. 
Specifically, this section deals with the impact of the bacterial inflammagens in question on 
coagulation kinetics (initiation of clotting cascade to final fibrin formation) and clot rheology. 
 
5.2. Techniques 
5.2.1. Thromboelastography  
 
Thromboelastography (TEG) is a non-invasive method of measuring the state, efficiency and 
viscoelasticity of blood coagulation. This technique stands as a hallmark tool within our 
research group along with microscopy. While measuring biomarkers involved in coagulation 
such as fibrinogen concentration, platelet count, factor V and prothrombin time is extremely 
useful, TEG offers a comprehensive approach for assessing the kinetics of clotting as it 
measures the cascade from propagation to fibrin formation and then degradation. 
Discernment can be made as to whether an individual’s state of coagulation is normostatic, 
hypercoaguable (rapid coagulation) or hypocoaguable (slow coagulation). This obviously has 
clinical utility and is appropriately utilized in healthcare; a hypercoaguable state infers 
increased thrombotic risk whereas a hypocoaguable state, in the more extreme cases, can be 
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used to detect bleeding disorders such as haemophilia. This technique is useful in surgery 
whereby drug administration is determined by TEG assessment.  It must be noted that this 
system serves to monitor the intrinsic pathway of coagulation and not the extrinsic, tissue 
factor-activated pathway.  
The TEG 5000 Thrombelastograph Hemostasis Analyzer was used in this study. WB, platelet-
rich plasma (PRP) or PPP collected in sodium citrate tubes is eligible for testing by a 
thromboelastography machine. The operating principle of thromboelastography is depicted in 
Figure 10. In this test, 340mL of either one of the aforementioned sample types and 20mL of 
0.2M calcium chloride (CaCl2) for clot initiation is carefully pipetted into the oscillating TEG 
cup. As sodium citrate blood collection tubes function to sequester calcium ions (a cofactor for 
coagulation), this exogenous CaCl2 is reintroduced into the blood or plasma to commence 
coagulation. As fibrin forms, or as the viscosity of the sample increases parallel to coagulation, 
a pin extending into the blood or plasma senses these changes and transfers the information 
to an electromagnetic transducer. A trace of the fibrin formation is then recorded and 
represented as a graph and numerical values.  
 
 
 
 
 
 
 
Figure 10: The working mechanism of a thromboelastograph. (Adopted from 
slideshare.net/drsumitg). 
 
The thromboelastograph records certain parameters that relate to clot size, strength and 
predominantly kinetics. Table 4 contains the TEG parameters assessed in this study, their 
description and relative units. In addition, the table includes whether a larger or smaller value 
of each parameter indicates a hypercoaguable or hypocoaguable state. 
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Table 4: TEG parameters assessed and their description, along with the direction towards a 
hyper- or hypocoaguable state within each parameter. 
Parameter 
Assessed 
Description Units Hypercoaguable Hypocoaguable 
R-value Latency time prior to initial 
fibrin formation (amplitude 
of 2mm) 
Time (minutes)  
↓ 
 
↑ 
α-angle  The speed of fibrin build 
up and cross linking (rate 
of clot formation); i.e. 
thrombin burst 
Degrees (°)  
↑ 
 
↓ 
Maximum 
Amplitude 
(MA) 
Maximum stiffness of clot; 
i.e. overall stability of the 
clot 
Millimetres  
↑ 
 
↓ 
Maximum Rate 
of Thrombus 
Generation 
(MRTG) 
The maximum velocity of 
clot growth observed or 
maximum rate of 
thrombus generation 
using G, where G is the 
elastic modulus strength 
of the thrombus in 
Dyn.cm-2 
Dyn.cm-2.s-1  
 
 
↑ 
 
 
 
↓ 
Time to 
Maximum Rate 
of Thrombus 
Generation 
(TMRTG) 
The time interval 
observed before the 
maximum speed of the 
clot growth 
Time (minutes)  
 
↓ 
 
 
↑ 
Total 
Thrombus 
Generation 
(TGG) 
The clot strength: the 
amount of total resistance 
generated during clot 
formation (total area 
under the velocity curve 
during clot growth) 
Dyn.cm-2  
 
↑ 
 
 
↓ 
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5.2.2. Rheometry 
 
Rheometry evaluates the rheological properties of a material. In the case blood, it is referred 
to as hemorheology. Due to the various constituents of blood, such as erythrocytes, platelets, 
white blood cells, plasma, and especially the clotting protein fibrin(ogen), the viscoelastic 
changes during and after the clot formation results in a unique profile when assessed with 
rheology. Accordingly, blood is classified as a non-Newtonian fluid – one whose viscosity 
varies according to stress applied. Discrepancies within the haematological system, such as 
increased fibrinogen concentrations during an acute phase response, alter the standard profile 
of blood clot rheology and can thus be compared to healthy controls. Surprisingly, data 
regarding blood with the addition of exogenous bacterial inflammagens is scarce or absent. 
In a rheometer, the initiation of clot formation up until terminal fibrin formation is assessed in 
a kinetic manner and thus is synonymous to the TEG (this assessment will thus be negated). 
However, after the clot has been formed, various stressors are applied to the material to 
understand how the sample (clot) responds or deforms to the force applied. Blood clots, with 
a special emphasis on fibrin, have inherent viscoelastic properties enabling them to deform 
under particular forces and recoil into its original structure. This is known as the linear 
viscoelastic (LVE) range. Similarly, it is the range in which forces can be applied to the sample 
without leading to sample destruction. However, when this force exceeds the LVE range of a 
sample, the physical components within the sample begin to break and thus deems the sample 
unable to recoil to its original state (the elastic threshold of the sample has been surpassed) 
– this is known as the nonlinear viscoelastic (NLVE) range.  
This study focuses on the response of clot networks to applied stress using a MCR 502 Anton 
Paar rheometer, which seems to be one of few assessing the effects of exogenous bacterial 
inflammagens on blood rheology. A rheometer is capable of various modes of testing. For our 
study, we performed oscillation tests whereby an increasing oscillatory stress is applied to the 
clots until molecular damage passes a certain threshold – data was obtained both within the 
LVE and NLVE range. Table 5 represents the rheology parameters utilized and their relevant 
descriptions. This section of the study was conducted in the Medical University of Vienna over 
the course of two weeks.   
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Table 5: Parameters assessed by the rheometer and their description as well as meaning if 
increased or decreased.  
Rheometry 
parameter 
Description Meaning if 
increased 
Meaning if 
decreased 
G' initial (G’LVE) Maximum strength/stiffness of fibrin 
clot., i.e. overall stability of the clot at 
rest 
The material is stiffer; 
fibres could be thicker 
or network denser 
The material is less 
rigid; possibly thinner 
fibres or looser fiber 
architecture 
G'max Stiffness of the clot when the network 
is maximally elongated/deformed; 
fibrin networks stiffen when they are 
deformed 
The clot is stiff at its 
maximum deformation 
The clot is weak at its 
maximum deformation 
Breakup Stress Shear stress needed to break the clot The clot can sustain 
higher stresses 
The clot sustains lower 
stresses 
Elastic Limit Marks the end of the elastic 
behaviour of the clot; Beyond the 
elastic limit the network starts to 
stretch out and rearrangement takes 
place  
The network allows 
higher deformations 
without experiencing a 
structural change 
The network 
experiences a 
structural change at 
lower deformations 
Linear viscoelastic 
behavior 
Elastic behaviour of the clot; 
Reversible deformation occurs, there 
is no structural change 
Higher clot stiffness  Lower clot stiffness  
Shear stiffening 
(G'max – G'min) 
All bending fluctuations are stretched 
out and the clot becomes less 
compliant; No more occurs the re-
arrangement of the network, but 
increasing stretching of the network 
to a final value (G´max)  
The clot stretches out 
well 
The clot does not 
stretch out well 
G´max – G´final Individual fibers and/or network 
extend until the clot breaks 
Slow breaking of the 
clot 
Brittle breaking of the 
clot 
G’ = Storage modulus (the ability to store energy in an elastic manner) 
 
5.3. Material and Methods 
5.3.1. Thromboelastography 
 
Naïve healthy platelet-poor plasma was subjected to TEG analysis to determine the subjective 
state of coagubility in each individual. The subjects’ PPP was then diluted with RgpA and 
immediately tested or incubated with recombinant RgpA for 30 minutes at an exposure 
concentration of 500ng.L-1; coagulation was then measured by the TEG to determine the effect 
of recombinant RgpA (purchased from Abcam; catalogue number: ab225982) on the efficacy 
of the clotting cascade. In this test, the 324uL of the naïve samples were diluted with 36uL of 
PBS (vehicle) to match the circumstances of the intervention group. Then, 340uL of the diluted 
naïve plasma was then placed in the TEG with 20uL of calcium chloride (CaCl2) and 
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measured. The CaCl2 returns calcium to the sample which is removed by the sodium citrate 
tube and required as a cofactor for a number of the relevant reactions in the coagulation 
cascade. Conversely, the intervention group (matched to the naïve TEG group) received an 
addition of 36uL of 5µg/L RgpA solution (in PBS) in 324uL of PPP. As mentioned, this was left 
to stand for thirty minutes before pipetted into the TEG machine with the addition of CaCl2. 
Following the addition of the cofactor required to commence coagulation, the test is promptly 
started in order to include the entire lag phase prior to clot formation (R-value).  
 
5.3.2. Rheometry 
 
Whole blood (WB) and PPP were subjected to rheometry analysis on an Anton Paar MCR 502 
with a plate-plate measuring system in order to determine the flow behaviour and deformation 
of samples. Kinetic as well as oscillation tests were run on all the samples at 37°C. A shear 
rate of 0,1% at a frequency of 1Hz was applied to WB and PPP samples during the kinetics 
test. In the oscillation analysis, an increasing shear rate of 1-5000Pa at 1rad/s was applied to 
all samples. For WB and PPP samples, 0,2M CaCl2 was used to induce coagulation. Samples 
received the addition of CaCl2 immediately before the sample was placed on the measuring 
plate and subjected to the kinetic test. The intervention groups, matched to the controls, were 
incubated with varying concentrations of RgpA and/or LPS (purchased from Sigma-Aldrich; 
catalogue number: SMB00610) from P. gingivalis. RgpA was exposed at 100ng.L-1 and 
250ng.L-1 whereas LPS was exposed at 20ng.L-1 alone or in combination with 100ng.L-1 RgpA 
to WB and PPP samples. 
 
5.4. Results 
5.4.1. TEG of healthy plasma exposed to RgpA 
 
TEG results of naïve and RgpA-exposed PPP is shown in Table 6. The results of the control 
group, albeit normal, serve as a basis for comparison with the intervention group. Naïve and 
RgpA-exposed samples are paired, i.e. subject X’s naïve run is compared with subject X’s 
intervention run.  
The effect exerted by this protease on viscoelastic parameters of clotting is substantial as all 
six parameters assessed exhibited significance. Overall, the protease in question shifted the 
state of coagulation to a more hypocoaguable one; this is reflected in each time-dependent 
parameter – namely the R-value (**), α-angle (**), MRTG (***), and TMRTG (**) – all of which 
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are increased (longer time taken). RgpA inhibits the ability of clots to initiate (increased R-
value) and cross-link (decreased α-angle) and also inhibits the rate of enzymatic function 
during fibrin synthesis (decreased MRTG & increased TMRTG). Therefore, it appears that a 
lagging of clotting processes in the presence of RgpA occurs.  
Other than time-dependent parameters, the TEG also assesses physical clot attributes such 
as relative stiffness and size. TTG is decreased in the presence of RgpA. This indicates a 
decreased clot strength and size – a result linked to the fibrin(ogen)olytic and hence fibrin-
diminishing ability of the protease. The RgpA group, surprisingly, exhibited clots with an 
increased MA – total stability and stiffness of clot. This is deemed unexpected as lower fibrin 
loads (due to fibrinogenolysis) would be expected to result in lower clot stability and stiffness. 
RgpA-induced biochemical changes in fibrin and network arrangement likely attribute to this 
enigma. While the increase in MA under RgpA exposure is a confusing result to explain, 
overall clot kinetics is slowed by RgpA prompting a state a hypocoagubility. The clots formed, 
albeit it stiffer, were also smaller and weaker than naïve clots. 
 
Table 6: TEG® results of naïve control PPP vs. 500ng.L-1 RgpA exposed PPP (matched).  
 
Statistical significance was established at p < 0,05 (* = p < 0.05; ** = p < 0.01; *** = p < 0.001). 
Due to technical implications, only 20 K-values were recorded. Data is represented as the 
mean ± standard deviation. 
 
5.4.2. Rheometry of healthy blood samples exposed to RgpA and LPS 
 
Table 7 shows the rheological data obtained from naïve and inflammagen-exposed whole-
blood and platelet-depleted plasma (PDP) samples. In PDP, both the exposures of RgpA and 
LPS from P. gingivalis enhanced the linear viscoelastic shear modulus (G’ initial and max). 
This indicates that these two bacterial factors interfere with the biochemical nature of clots 
thereby resulting in a rheological profile of increased stiffness (G’). Shear stiffening was 
Parameter Control RgpA p-value 
R (min) 10.02 ± 3.12 11.97 ± 4.57 0.0011 (**) 
α angle (°) 63.59 ± 7.79 59.63 ± 8.89 0.0014 (**) 
MA (mm) 24.57 ± 6.21 29.37 ± 7.35 0.0211 (*) 
MRTG (Dyn.cm-
2.s-1) 
4.2 ± 1.72 3.37 ± 1.73 0.0001 (***) 
TMRTG (min) 11.56 ± 3.44 13.84 ± 5.29 0.0032 (**) 
TTG (Dyn.cm-2) 
167.7 ± 56.79 149.8 ± 43.28 0.0224 (*) 
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increased by both interventions, with LPS exhibiting a more prominent effect. Conversely, LPS 
results in clots that break at larger shear stresses (breakup stress) while RgpA significantly 
lowers the breakup threshold. RgpA also lowers the elastic limits of clots. This decrease in the 
breakup stress and elastic limit can be explained by the fibrin(ogen)olytic ability of RgpA 
whereby a decrease in clot size and mass will result in a weaker, smaller clot; this (decrease 
in breakup stress and elastic limit) is synonymous to TTG measured by the TEG (Table 6).  
In the WB samples, LPS forms less rigid and less stiff clots in WB whereas the opposite effect 
is observed in PDP. LPS decreased G’ initial at both concentrations while G’ max was 
decreased compared to the naïve samples at 20μg·L-1 and increased compared to the naïve 
samples at 20μg·L-1. Conversely, RgpA increased both G’ initial and max thereby resulting in 
stiffer clots; the same effect was observed in PDP. This effect is somewhat unexpected as the 
fibrin(ogen)olytic effect of RgpA would be expected to result in a smaller clot (lower fibrin load 
due to decrease in fibrinogen); this correlates to the MA (Table 6) values in which RgpA-
exposed clots exhibited increased stiffness. RgpA also decreased the breakup stress and 
elastic limit in WB samples. The detection of increased clot stiffness in the presence of RgpA 
by both the TEG and rheometer strengthens this reliability of this result, as it does with the 
breakup stress and elastic limit with TTG. With regards to breakup stress both concentrations 
of LPS lowered the breakup stress of clots.  
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Table 7: Rheological data of WB and PDP samples.  
Sample G' initial [Pa] G' max [Pa] 
Breakup Stress 
[Pa] 
Elastic 
Limit [Pa] 
Shear 
stiffening 
(G' max – 
G' min) 
[Pa] 
 
Whole-blood 
 
Control 1 174.12 ± 25.29 207.54 ± 49.07 441.47 ± 192.88 
17.75 ± 
2.67 
54 
Control 1 + RgpA 
(100 ng·L-1) 
208.63 ± 13.35 227.48 ± 16.22 339.25 ± 113.95 
16.55 ± 
5.36 
41 
Control 2 315.87 ± 21.48 607.28 ± 48.81 1239.07 ± 417.61 
26.13 ± 
3.32 
331 
Control 2 + PG 
LPS (20 ng·L-1) 
291.02 ± 26.74 653.41 ± 77.02 1202.23 ± 154.12 
17.12 ± 
2.12 
396 
Control 2 + PG 
LPS (20 μg·L-1) 
253.99 ± 37.74 577.73 ± 69.65 1041.16 ± 122.53 
16.09 ± 
3.37 
349 
 
Platelet-depleted plasma 
 
Control 1 40.55 ± 2.07 551.77 ± 30.02 912.36 ± 193.61 2.89 ± 0 511 
Control 1 + RgpA 
(250 ng·L-1) 
45.34 ± 7.5 570.52 ± 64.78 737.63 ± 156.51 
2.52 ± 
0.32 
525 
Control 3 48.86 ± 5.3 
561.67 ± 
113.36 
757.54 ± 246.59 
3.39 ± 
1.81 
513 
Control 3 + PG 
LPS (20 ng·L-1) 
71.19 ± 5.84 762.39 ± 52.03 901.7 ± 0.57 3.35 ± 0.4 691 
Data expressed as mean ± SD. 
 
5.5. Discussion 
5.5.1. The effects of RgpA on the kinetics of coagulation 
 
Coupled to PD and AD are abnormalities in coagulation predominantly characterised by 
hypercoagulability (Adams et al., 2019, Bester et al., 2015). This is a major contributing 
mechanism to the prothrombotic state observed in PD and AD and contributes to an overall 
risk of cardiovascular mortality. Furthermore, periodontal disease too exhibits a similar 
phenotype in the clotting system (Dikshit, 2015, Senini et al., 2019). The question that arose 
is if whether periodontopathic bacteria and their inflammagens may be responsible, in part, for 
the aberrations in clotting processes seen in PD, AD and periodontal disease. Even more so, 
in light of the new data presented in this thesis that shows the presence of RgpA in the blood 
of PD and AD patients, the effects that P. gingivalis and its inflammagens have on clotting is 
warranted. Thus, the second component of this literature seeks to determine the impact of 
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RgpA on the clot kinetics, rheology and terminal (at the point of a stabilised clot, before 
fibrinolysis) fibrin load and network architecture.  
In terms of clot kinetics, RgpA shifts the normostatic state of coagulation to a more 
hypocoaguable one as reflected by the four time-dependent TEG parameters (R-value, α-
angle, MRTG and TMRTG) in Table 6. Lagging of clotting processes is believed to be induced 
by the fibrin(ogen)olytic activity of RgpA. To explain further, as exogenous RgpA is added to 
a blood sample, fibrinogen cleavage occurs subsequently resulting in less substrate available 
for fibrin synthesis and thus clot formation; since the TEG records values only when the clot 
has reached a certain size (e.g. 2mm for the R-value), a lower load of fibrinogen in a sample 
(here, due to RgpA activity) will lead to a longer time taken to achieve a certain clot size and 
hence register a value for a given TEG parameter. Supporting this ideology, exogenous RgpA 
yields a clot that is smaller in size and mass compared to naïve clots (TTG). This is consistent 
with the process of fibrinogen cleavage whereby increased fibrinogenolysis results in 
decreased fibrin synthesis and thus lower clot size and mass. Inhibiting haemostasis in this 
manner aids P. gingivalis in heme acquisition, entry and dissemination into physiological 
systems and contributes to increased bleeding tendencies observed in periodontitis. 
Interestingly, this hypocoaguable-promoting effect of RgpA is in contrast to the 
hypercoaguable-favouring effects of LPS (Pretorius et al., 2016). 
Apart from fibrinogen, RgpA has a plethora of targets in plasma, some of which include plasma 
proteins and platelets receptors (Imamura et al., 2001b, Imamura et al., 1997). The modulation 
of platelets via RgpA (Lourbakos et al., 2001) can prompt aberrant function and impede the 
efficiency of coagulation. It is possible that RgpA also acts on certain clotting factors which 
lead to disturbances in the efficiency of clot formation. When analysing the α-angle the time 
taken to achieve a certain magnitude of crosslinking is lengthened (smaller °) by RgpA. Factor 
XIII is responsible for coordinating the crosslinking of fibrin and may be modulated by RgpA. 
However, there seems to be little or no data on RgpA and its functionality with factor XIII. The 
activation of factors IX and X as well as the release of thrombin from prothrombin by RgpA 
(Imamura et al., 2001b, Imamura et al., 1997, Imamura et al., 2001a) is noted and can alter 
the enzymatic balance of the clotting cascade; but contradictory to the overall effect, increases 
in these enzymes, especially thrombin which is a catalyst for fibrin synthesis, would be 
expected to prompt a hypercoaguable state. Although such an effect may occur, it is most 
likely masked and overpowered by RgpA-mediated fibrinogenolysis – the most probable 
cause of the observed shift of plasma samples to a hypocoaguable state. 
The MA parameter produced unexpected results. RgpA-exposed plasma exhibited a higher 
MA value (29.37) than the control group (24.57) with a significance difference of p < 0.05 (*). 
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This indicates that the plasma incubated with RgpA yields a clot that is stiffer and more stable 
than naïve clots unexposed to the protease. Rheological analysis of clots also exhibited and 
supports this stiffening in the presence of RgpA (Table 7). As mentioned, RgpA acts on clotting 
factors and platelets – two factors which determine the physical properties of clots. 
Manipulation of these two factors by RgpA may alter the biochemical arrangement and 
structure; for example, RgpA may alter the function of factor XIII and result in abnormal fibrin 
crosslinking characteristic of a stiffer, more stable clot. Nonetheless, this result is difficult to 
explain, and requires further biochemical investigation.  
5.5.2. The effects of RgpA and LPS on clot rheology 
 
This study is one of few assessing the role of bacterial products on rheological properties of 
blood clots. Here, it is shown that RgpA-exposed clots are stiffer, break at lower stresses and 
are less deformable under stress when compared to control clots. These effects were 
consistent in both WB and PDP samples. RgpA seems to impede the inherent elastic capacity 
of clots. This will result in clots that are less responsive (deformable) and undergo destruction 
under certain forces. In a clinical perspective, this prompts bleeding tendencies observed in 
periodontal disorders (Page et al., 1978) as inadequate clot formation, strength, deformability 
and stability hinders effective hemostasis. Supporting the inconspicuous MA result obtained 
by the TEG, rheological data of RgpA-exposed clots also exhibits an increase in clot stiffness. 
While speculations regarding RgpA and its possible modulation of clotting factors and platelets 
are put forth, this finding requires comprehensive biochemical investigation. 
Interestingly, the effects imposed on rheological properties of clots by P. gingivalis’ LPS differ 
according to sample type, e.g. PDP & WB. PDP clots exposed to LPS are stiffer and break 
under higher stresses when compared to controls whereas LPS-exposed WB clots are less 
stiff compared to controls. In WB, the mean breakup stress is lower in LPS-clots which relates 
to decreased stiffness. LPS-exposed PDP clots also present with a larger degree of elasticity 
than controls, a result in contrast to that of LPS-exposed WB clots RgpA-exposed clots. These 
differences observed between WB and PDP can be attributed to the presence (and response 
of) erythrocytes and platelets in WB. Erythrocytes increase spaces within fibrin networks and 
possess inherent pliability and a significant deformability capacity; this contributes to a 
decreased integrity and ‘stiffness’ of clots and likely has a role to play the result of decreased 
stiffness in LPS WB clots. Additionally, erythrocytes bind fibrinogen (Litvinov and Weisel, 
2017) and influence clot properties in this manner. Platelets may also act as contributors to 
decreased stiffening observed in WB. Platelets play an important role in orchestrating clot 
formation and architecture. They secrete factor XIII, the clotting factor responsible for forming 
Stellenbosch University https://scholar.sun.ac.za
 68 
 
crosslinks. While this factor functions to increase the integrity of fibrin networks, the presence 
of LPS and its modulation of platelet receptors (Saluk-Juszczak et al., 2000, Lopes Pires et 
al., 2017, Senini et al., 2019) may induce atypical function. For example, a study concluded 
that LPS reduced the levels of clotting factor XIII and additionally noted alterations to this 
protein (Pabst et al., 2008). Furthermore, abnormalities in platelets and subsequent factor XIII 
handling results in smaller, weaker and less stiff clots. These perturbations in platelet function 
and factor XIII induced by LPS could account for decreased stiffness observed in WB clots. 
Nonetheless, without red blood cells, platelets and other WB factors, LPS-exposed PDP clots 
are more densely packed which typically will result in increased clot integrity as indicated by 
increased G’ and breakup stress values. Ultimately, compared to RgpA, LPS-exposed clots 
are more capable of deforming in response to a stress and according to sample type (WB & 
PDP) exhibit different trends with regards to stiffness. 
Changes that occur to the viscoelastic and rheological properties of blood clots induced by 
RgpA and LPS are substantial. While the two techniques employed to study these changes 
have derived insightful data, further coagulation studies, preferably in animal models, involving 
these virulent factors is warranted. 
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CHAPTER 6: PURIFIED FIBRINOGEN MODEL 
 
6. The effects of bacterial inflammagens from P. gingivalis on fibrin load and network 
structure 
 
6.1. Introduction 
 
RgpA, as a proteolytic enzyme, is capable of cleaving a number of target proteins. With 
relevance to the coagulation system, RgpA exerts a noted fibrin(ogen)olytic effect. This 
cleavage of fibrin(ogen) may contribute to fibrinogen dyshomeostasis and defective 
coagulation seen in inflammatory conditions, particularly those that exhibit associations with 
periodontal disease. The proteolysis of fibrin(ogen) by RgpA will thus be assessed, by 
microscopy, in this section. 
In this chapter, purified fibrinogen is used in order to assess the effects of bacterial 
inflammagens on the clotting constituent without any confounding coagulation factors such as 
platelet and clotting factor interference. Purified fibrinogen is exposed to RgpA for 30 minutes 
prior to clot formation via thrombin-catalysis; the networks are then assessed via microscopy. 
Since LPS from P. gingivalis forms a complex with RgpA (Li and Collyer, 2011) and since 
these two molecules are present in a system at the same time, the clotting-related effects of 
RgpA in the presence of LPS will also be studied in order to match realistic physiological 
scenarios.  
In this chapter, by using fluorescent fibrinogen and confocal microscopy, and SEM, the 
research question we aim to address here is: ‘How does inflammagens from P. gingivalis 
affect blood clotting?’ Specifically, this section deals with the impact of the bacterial 
inflammagens in question on fibrin load and terminal network structure. 
6.2. Techniques 
6.2.1. Confocal Microscopy 
 
With relevance to coagulation, fluorophore-conjugated fibrinogen allows researchers to study 
a purified fibrinogen model whereby the network structure and architecture of fibrin is 
fluorescent and easily observed. This greatly aids the understanding of how molecules 
(inflammagens) affect fibrin(ogen) and resulting clot formation. Relevant to the aim of this 
section, the load of fibrin and network formed can be discerned as well. Recently, using 
confocal techniques, it was demonstrated that LPS leads to abnormal clot formation 
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characteristic of dense matter deposits (Pretorius et al., 2018b). The effect on (fluorescent) 
fibrin clots formed from fibrinogen exposed to inflammagens from P. gingivalis can be studied 
in this regard.  
 
6.2.2. Scanning Electron Microscopy 
 
Ultrastructural changes to constituents of blood are favourably studied with electron 
microscopy. As we study the clotting component of blood (protein), transmission electron 
microscopy is negated; SEM thus poses as the desired option to study the structure and 
network arrangement of fibrin. Here, a focused beam of electrons are emitted onto a sample 
coated with carbon. The topography of the sample is recorded and due to the electron-based 
nature of this technique, the resultant micrographs are of impeccable resolution.  
It has been noted that inflammatory molecules, bacterial LPS, cigarette smoking and glucose 
can alter the morphology of RBCs, platelets and fibrin (Pretorius, 2013, Pretorius et al., 2013, 
Bester and Pretorius, 2016, Pretorius et al., 2018b). Although other microscopy techniques 
are adequate to study such changes, SEM stands as the primary mode of assessment in 
terms of ultrastructural analysis. Furthermore, results obtained by TEG and confocal 
microscopy are translatable to SEM micrographs (e.g. hypercoagulability in TEG and 
hyperactivated platelets in confocal), provided the same sample is used. 
A Merlin Field Emission Scanning Electron Microscope (FE-SEM) from Carl Zeiss was utilized 
in order to view the ultrastructural changes that occur to fibrin fibres and networks with the 
addition of bacterial products from P. gingivalis. 
 
6.3. Methods and materials 
6.3.1. Confocal microscopy using fluorescent fibrinogen 
 
Purified human fluorescent fibrinogen (Alexa 488) (ThermoFisher; catalogue number: F13191) 
was prepared to a final concentration of 2mg.mL-1. Thrombin, obtained by the South African 
National Blood Service, was solubilized in PBS containing 0.2% human serum albumin to 
obtain a concentration of 20 U.mL-1. In order to form clots, 5mL of fibrinogen received 2,5mL 
of thrombin (2:1 ratio) to stimulate the formation of fibrin networks. The sample was then fixed 
with 10% NBF and then washed with PBS. The sample was then blocked with 5% goat serum 
(diluted with PBS) and incubated with gingipain R1 polyclonal antibody (1:100 in goat serum) 
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for one hour at room temperature. The samples were washed with PBS and a coverslip was 
mounted along with Dako fluorescence mounting medium. The recombinant protease was 
exposed at two different concentrations, 100 and 500 ng.L-1 (final exposure), and incubated 
for 30 minutes.  Clots were also viewed with the confocal microscope and fluorescent 
fibrinogen was excited at 488 nm, with emission measured at 508 to 570 nm. As the gingipains 
antibody used above has the same excitation and emission as the purified fibrinogen, we could 
not trace the added gingipains by using this antibody. 
 
6.3.2. SEM of purified fibrinogen exposed to RgpA and LPS 
 
Purified fibrinogen received the addition of RgpA and LPS at exposure concentrations of 
500ng.L-1 and 10ng.L-1, respectively, and left to incubate with these inflammagens for 30 
minutes prior to SEM preparation.  
10μL of purified fibrinogen (exposed or unexposed) was pipetted onto a 1cm diameter glass 
cover slip. The pipette tip is then removed, forcefully yet carefully bent and then used to create 
a smear on the circular glass slip. 5µL of thrombin was then added into the drop of 
PPP/fibrinogen and carefully mixed. The sample was left to stand for five minutes to allow to 
adhere to the glass surface. The slip is then lifted using tweezers and translocated to a 24-
well plate. The sample was then washed using PBS and left to rest for ten minutes. After PBS 
removal, 10% NBF – enough to cover the sample – is added to the well as a fixative using a 
Pasteur pipette and left for 20 minutes. After removing the fixative, the sample was washed 
three times with PBS. Working in a fume hood, a glass pipette was used to add 2-3 drops of 
osmium tetroxide – a potent fixative optimal for SEM – to sample wells and left to incubate for 
30 minutes. After discarding of the osmium tetroxide, the samples were again washed with 
PBS 3 times. The samples were then dehydrated with increasing concentrations of ethanol – 
30%, 50%, 70%, 90% and 100% – each for three minutes. After removing the last of the 100% 
ethanol, hexamethyldisilazane (HMDS) is added as the terminal dehydrating agent. Three 
drops of HMDS were added to each sample well and left for 30 minutes. The slips were 
carefully lifted slightly to prevent adhesion to the plate-surface during HMDS incubation. 
Lastly, slips are removed from each well and placed onto a glass microscope slide ready for 
subsequent carbon coating and SEM analysis.   
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6.4. Results 
6.4.1. Confocal micrographs of fibrin networks exposed to RgpA and LPS 
 
Confocal micrographs displaying fibrin networks formed from naïve or inflammagen-exposed 
purified fibrinogen (Alexa 488) is displayed in Figure 11. Naïve fibrin networks (A-B) 
demonstrate the normostatic arrangement of clot architecture (healthy clot). There are 
consistent distances between fibres and synonymous branching points. However, when 
purified fibrinogen is incubated with recombinant RgpA prior to thrombin exposure, the fibrin 
network formed is almost non-existent (C-D). Fibrinogenolysis mediated by RgpA explains this 
observation. There seems to be no visible network but rather small fragments of fibrin possibly 
formed from fibrinogen uncleaved by RgpA. Conversely, LPS exposure results in a substantial 
clot formed (E-F). However, the clot deviates from what is considered normal and healthy; the 
fibrin network is more densely packed with less spaces between fibres resembling dense 
matter deposits. This phenomenon is also credible to LPS from other species of bacteria 
(Pretorius et al., 2016). When RgpA and LPS are co-incubated with purified fibrinogen (G-H) 
preceding thrombin catalysis, the effect of LPS (causing dense matter deposits) is manifested 
more as opposed to RgpA’s deleterious effect on fibrin formation. The fibrinogenolytic activity 
of RgpA is thus hindered and negated in the presence of LPS; LPS seems act on fibrin 
architecture as if RgpA was absent in the sample.  
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Figure 11: Confocal images (63x magnification) of 2mg/mL purified fibrinogen with and 
without the addition of bacterial inflammagens from P. gingivalis. A-B) Naïve fibrin architecture 
representative of healthy clots. C-D) Clot formed form purified fibrinogen exposed to 500ng.L-
1 RgpA. E-F) Purified fibrinogen exposed 10ng.L-1 LPS. G-H) Fibrin network after purified 
fibrinogen was co-incubated with 500ng.L-1 RgpA and 10ng.L-1 LPS.  
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6.4.2. SEM micrographs of fibrin networks exposed to RgpA and LPS 
 
Ultrastructure of fibrin networks analysed by SEM are shown in Figure 12. Naïve fibrin 
architecture (A-B) is representative of healthy clots. Again, as with the confocal micrographs, 
spaces between fibres and the nature of branching points is consistent, forming a ‘spaghetti-
like’ network. When exposed to purified fibrinogen, RgpA results in little or no fibrin formed (C-
D) after the zymogen undergoes thrombin catalysis. Consistent with the confocal results 
obtained (Figure 11), the fibrin(ogen)olytic effect of RgpA is prominent. The particles present 
in the micrographs may be residual particles of fibrin(ogen) similar to the fluorescent fragments 
observed in the confocal micrographs in Figure 11 (C-D). Again, synonymous to the confocal 
results, co-incubation of RgpA with LPS yields a fibrin clot (E-F), thereby negating the 
(complete) fibrinogenolytic effect of the protease. The fibrin clot formed is extremely aberrant 
in form and reflects a clot characteristic of dense matter deposits. The effect of LPS thus 
dominates whereas the proteolytic activity of RgpA is masked as reflected in the confocal data. 
To explain this inhibition of RgpA’s proteolytic activity, an association between the two 
bacterial inflammagens during co-incubation must occur; alternatively, LPS may bind 
fibrinogen molecules (de Waal et al., 2018) with a higher affinity than RgpA thereby disabling 
the protease from reaching the zymogen.  
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Figure 12: SEM micrographs of fibrin clots formed by thrombin-mediated catalysis of purified 
fibrinogen incubated with or without inflammagens from P. gingivalis. A-B) Naïve fibrin clots. 
C-D) Fibrin clots formed from fibrinogen exposed to 500ng.L-1 RgpA prior to thrombin addition. 
E-F) Fibrin clots formed from fibrinogen exposed to 500ng.L-1 RgpA and 10ng.L-1 LPS prior to 
thrombin addition.  
 
6.5. Discussion 
 
6.5.1. The effects of exogenous RgpA on fibrin load and network formation using 
purified fibrinogen  
 
Although fibrinogen cleavage by RgpA is a defined process, the impact that this proteolysis 
has on fibrin network load and arrangement using modern techniques such as SEM and 
confocal microscopy is yet to be discerned. Here, a purified fibrinogen model was used to 
determine the influence that P. gingivalis’ key protease has on the outcome of a thrombin-
catalysed clot. Since LPS from the same bacterial species forms complexes with RgpA and 
even alters its structure (Takii et al., 2005), co-exposure of these two bacterial products 
A B 
C D 
E F 
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enables the discernment of any inhibition or enhancement promoted by LPS on RgpA-
mediated fibrin alterations.  
Thrombin-catalysed fibrin formation is prevented when the zymogen is incubated with 
500ng.L-1 RgpA (Figure 11 & 12). Fibrinogen cleavage as a result of RgpA exposure depletes 
the substrate available for fibrin synthesis thereby reducing the load of clot formed. As seen 
in Figure 11B & 12B (500ng exposure), a clot network is absent. Hence, RgpA exhibits great 
fibrin(ogen)olytic ability. In the confocal micrographs, very few fluorescent fragments are 
present; these are likely strands fibrin formed from naïve (unreached by RgpA) fibrinogen 
remaining in the sample. These residual fragments can also be seen in the SEM micrographs. 
This abrogation of clot formation by RgpA decreases hemostatic capabilities and contributes 
to bleeding and inflammation seen in periodontal disease (Imamura et al., 1995). In WB and 
plasma, however, this fibrin depletion and clot absence is not as prominent (as inferred by 
TEG and rheological oscillatory tests). Inhibitors of gingipains in plasma, such as endogenous 
protease inhibitors and other target proteins such as albumin (Imamura et al., 1995), likely 
account for this difference observed between purified fibrinogen and blood samples. 
In solidarity, RgpA hinders the formation of fibrin in purified fibrinogen samples. However, co-
incubation of RgpA with LPS yields opposing results in the same sample. For instance, co-
incubation of these two inflammagens allows a clot to form (Figure 11 G-H & Figure 12 E-F) 
whereas RgpA incubation alone abolishes visible clot formation. This indicates that LPS 
hinders the ability of RgpA to cleave fibrinogen and reduce fibrin load. This likely occurs due 
to binding and complex formation of these two factors from P. gingivalis (Takii et al., 2005); 
biochemical changes that occur to RgpA due to LPS binding may render some its proteolytic 
activates redundant. Whether RgpA has a stronger binding affinity for LPS as opposed to 
fibrinogen is questionable and relevant. Furthermore, the clot that does form is 
characteristically abnormal and resembles dense-matter deposits – a clot structural variant 
that poses significant cardiovascular risk and is induced by other types of LPS (Pretorius et 
al., 2018b). It therefore seems that when these two inflammagens are co-exposed to 
fibrinogen, the fibrin(ogen)olytic effect of RgpA is masked by LPS which instead is chiefly 
responsible for determining the outcome of the clot e.g. dense matter deposit instead of fibrin-
depletion induced by RgpA. 
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CHAPTER 7: CONCLUSION 
 
For quite some time now, the role of microbial dysbiosis in PD and AD has received much 
attention (Wu et al., 2017a, Roy Sarkar and Banerjee, 2019, Dutta et al., 2019, Friedland and 
Chapman, 2017, Ilievski et al., 2018). While the gut microbiota remains the focal microbial 
residence investigated in most neurodegenerative studies, the influence of the oral 
microbiome on PD and AD is being unravelled and shifting the spotlight from gut to oral 
microbes. P. gingivalis – the keystone pathogen of the oral cavity – is largely responsible for 
oral dysbiosis and is capable of prompting periodontal disease in solitude. It has also been 
shown that P. gingivalis has a significant effect on systemic inflammation (Arimatsu et al., 
2014, Zhang et al., 2018) which is believed to orchestrate systemic dyshomeostasis 
associated with periodontal disease, and thus the manifestation of comorbidities such as PD 
and AD.  Relevantly,  P. gingivalis is significantly associated with both PD (Kaur et al., 2016, 
Chen et al., 2017b) and AD (Ding et al., 2018, Chen et al., 2017a, Carter et al., 2017, Ganesh 
et al., 2017) thereby suggesting a more intimate role of this periodontopathic anaerobe in 
neurodegenerative pathology. Relevantly, recent findings of DNA and gingipains from P. 
gingivalis in the brains of AD patients substantiate the associations between periodontal 
disease and neurodegeneration and hence inspired the ideology of this thesis – identifying 
RgpA in the blood of PD and AD populations. 
This study is the first to discover the presence of RgpA in the blood (or a system exterior to 
the oral cavity) of patients afflicted with PD. This finding substantiates numerous associations 
found between periodontal disorders and PD (Kaur et al., 2016, Chen et al., 2017b) and offers 
novel insight into disease pathogenesis. A significant level of the protease was also detected 
in the haematological system of AD individuals. This result along with the finding of P. 
gingivalis in the brains of Alzheimer’s patients (Dominy et al., 2019) suggests that this 
pathological bacterium persists in circulation and enters other physiological systems such as 
the central nervous system where pathological processes can ensue. With confidence, it 
seems plausible that P. gingivalis stands as the direct link between periodontal disease and 
neurodegeneration. Relevantly, inhibitors of gingipains are being tested and implemented for 
therapeutic reasons (Dominy et al., 2019, Kariu et al., 2017, Singh et al., 2017) with the desire 
of disease prevention and amelioration. The biomarker potential of RgpA, in terms of 
diagnostics and prognostics, is highlighted. Further research is required to reveal the degree 
of impact that this bacterium has on the manifestation of not only neurodegenerative disease, 
but also the cohort of chronic inflammatory to which periodontitis is associated.  
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Periodontal disease, as well as PD and AD, present with abnormalities in the functioning and 
efficacy of the coagulation system that typically manifest as a hypercoagulable and thus 
prothrombotic state. The question that arose, especially in light of P. gingivalis being found in 
the brains of AD patients (Dominy et al., 2019) and in the blood of PD and AD patients (thesis 
in hand), is whether periodontopathic bacteria can have a significant effect on clotting 
processes and thus can contribute to overall increased cardiovascular risk observed in 
inflammatory conditions. The effects of RgpA on the kinetics of clotting, rheology of clots, and 
terminal fibrin load and network architecture is thus of interest. 
The effect that RgpA exerts on the coagulation system is extensive. In a reductionist-type 
purified fibrinogen model, RgpA completely diminishes clot formation to the point of little or no 
fibrin detection as assessed by confocal and scanning electron microscopy. Hence, RgpA 
promotes hypocoagubility. Interestingly, this effect is masked in the presence of LPS PG 
where instead it imposes its effects of anomalous clot formation characteristic of dense matter 
deposits. In WB and plasma samples, however, clot formation still occurs as indicated by TEG 
and rheometry analysis. This suggests that a degree of inhibition of RgpA-mediated 
fibrin(ogen)olysis originates from plasma, possibly enforced by albumin. Nonetheless, RgpA 
induces significant viscoelastic changes in WB and plasma and causes normostatic 
coagulation to deviate towards a state of hypocoagubility. In the presence of this protease the 
kinetics of clot formation is hindered, fibrin load and clot size is smaller, and the deformation 
capacity of clots is diminished due to a stiffer network. These significant viscoelastic changes 
promoted by RgpA can contribute to coagulation defects in diseased states if the bacterium is 
present. Hence, whole-blood clotting efficiency in the presence of bacterial inflammagens from 
P. gingivalis warrants further investigation as does the identification of this bacterial species 
and its virulent factors in periodontal and systemic disease.  
Overall, the pathogenesis of PD and AD is complex (Figure 13). Environmental and genetic 
factors contribute to the development and manifestation of neurodegeneration (1). Distinctive 
hallmark characteristics of PD and AD are amyloid β and α-synuclein accumulation, 
respectively, along with shared defects such as mitochondrial dysfunction, decrease in 
synapses and neuronal loss (2). Cardiovascular complications are widespread among PD and 
AD and as a result, cardiovascular events are a common mode of mortality among these 
patients. Hence, CVD is an important pathophysiological association to PD and AD (3). As 
mentioned, gut dysbiosis is prevalent in PD and AD (4) and highlights the impact that bacteria 
may contribute to pathology. Inflammation is an integral mechanism in the pathogenesis of 
PD and AD (5). The immune system expresses a notable degree of over activity and 
dysregulation which manifests as systemic inflammation, a factor which drives 
pathophysiological processes. What is relevant to this literature, however, is the implication of 
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bacteria and their inflammagens and their potential as novel biomarkers. RgpA, according to 
the results obtained in this thesis, is significantly present and both PD and AD populations and 
therefore may serve as a useful biomarker in terms of diagnostics and prognostics, or even 
as the target of therapy – more research is required to determine optimal application. 
Nonetheless, bacterial inflammagens, with their impact on inflammation and oxidative stress, 
may contribute to implications seen in the haematological system such as erythrocyte 
eryptosis, platelet hyperactivity, fibrin(ogen) dyshomeostasis and hypercoagulation. With the 
our novel findings that RgpA from P. gingivalis is present in the blood of PD and AD patients 
and that it exerts a prominent effect on clotting process, more insight is provided into the 
complex pathogenesis of both these disorders and highlights the role and biomarker potential 
of bacterial inflammagens, such as RgpA.  
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Figure 13: PD and AD express a complex pathophysiological profile with the presence of 
bacterial inflammagens. Environmental and genetic factors (1) lead to the development of PD 
and AD (2) whilst comorbidities such as CVD (3) soon manifests. The gut microbiome (4) 
becomes dysbiotic and contributes to CNS dysfunction and systemic inflammation (5). 
Ultimately, in relation to the clotting system, an overall state of hypercoagulability is induced. 
 
Ultimately, with relevance to clinical prospects, RgpA has been identified, for the first time, in 
the haematological system of both PD and AD populations; this offers novel insight for the 
aetiology, diagnosis and treatment of both neurological disorders. Ultimately, in terms of the 
bioactive effects of this gingipain in the coagulation system, RgpA exerts a hindering effect on 
clot kinetics, reduces total clot size and alters clot rheology to form stiffer, less pliable clots. 
RgpA also diminishes and abrogates fibrin formation and network development – this effect 
was dampened in the presence of LPS from P. gingivalis suggesting a role of LPS in nullifying 
the proteolytic effect of RgpA. 
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Appendix C: Blood-donor Consent Form 
 
 
NAME OF CONDITION______________ 
 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
Circulating inflammatory biomarkers and dysregulated coagulation in inflammatory 
conditions 
 
REFERENCE NUMBER: 9521 
 
PRINCIPAL INVESTIGATOR: Prof E Pretorius 
 
ADDRESS: Department of Physiological Sciences, Faculty of Science, 
Stellenbosch University, STELLENBOSCH 
 
 
CONTACT NUMBER: 0829295041 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please 
ask the study staff or doctor any questions about any part of this project that you do 
not fully understand.  It is very important that you are fully satisfied that you clearly 
understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary and you are free to decline to participate.  If you say 
no, this will not affect you negatively in any way whatsoever.  You are also free to 
withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines for 
Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines 
for Research. 
 
Control (mark with x)  
Inflammatory disease (mark with x) 
  
UNIQUE ETHICS NUMBER: 9521  
Left-over blood will be stored and used for 
similar studies, e.g. clearance numbers: 6399; 
1952; 6983; 6592; 
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What is this research study all about? 
You are invited to participate in research study conducted by Prof Resia Pretorius.  
This information leaflet is to help you to decide if you would like to participate.  Before 
you agree to take part, you should fully understand what is being involved in this 
research study. Your medical practitioner and/or phlebotomist will explain the reason 
for the drawing of blood.  As part of this current research study, 4 blood tubes will be 
drawn from you.  First tube will be sent to pathology laboratory or analyzed by 
ourselves, to determine your inflammatory status by looking at inflammatory markers 
like CRP levels. (An increase in CRP levels may influence the shape of the red blood 
cells, platelets and fibrin). The other 3 tubes will be used for our laboratory for 
haematological (blood) analysis, using specialized microscopes and specialized 
equipment for biochemical blood molecule (biomarker) analyses.  
 
The research team members are investigating the physiology and functioning of cells 
and circulating inflammatory molecules in your blood. This will be done by using 
specialized microscopes (that can magnify up to 100 000x (called an electron or a 
confocal microscope) and an instrument called a flow cytometer). We will also look at 
your blood using nanobiosensors, developed by prof Willie Perold and his research 
students from the Engineering Department.  We will store a part of your sample that 
is not used, for later analysis in similar studies, so that we do not waste samples. 
 
Why have you been invited to participate? 
We are recruiting  either healthy controls or individuals with inflammation and/or 
cardiovascular disease.   
OR 
Your medical practitioner wishes to obtain an individualized biomarker analysis of your 
inflammatory profile.  He/she will discuss the results with you. 
 
What will your responsibilities be? 
You will donate 4 tubes of blood (20 ml).  If you choose not to participate in this 
research study, you will still receive the standard care form your medical practitioner.  
You have no obligation to participate. 
 
Will you benefit from taking part in this research? 
There are no personal benefits but results generated from this study will allow researchers to 
determine the physiology of healthy clotting and red blood cell structure and will be used to 
test novel nanobiosensors for blood clotting analysis, constructed by the members of the 
Faculty of Engineering, Stellenbosch University.  If your medical practitioner has requested 
the analysis, via our SUNguis blood laboratory, he/she will share the results with you. We as 
SUNguis blood laboratory will not be involved in any diagnoses. We will simply provide your 
medical practitioner with results generated in our laboratory using our point-of-care blood 
analysis devices or state-of-the-art research equipment. 
 
Are there in risks involved in your taking part in this research? 
The Venipuncture (i.e. drawing blood) is normally done as part of routine medical care and 
presents a slight risk and discomfort. Drawing blood may result in a bruise at the puncture site, 
or less commonly swelling of the vein, infection and bleeding from the site. For your protection, 
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the procedures will be performed under sterile conditions by your medical practitioner or by a 
trained phlebotomist. 
 
If you do not agree to take part, what alternatives do you have? 
none 
 
Who will have access to your medical records? 
There will be access to any medical records only to determine previously obtained 
glucose levels and cholesterol levels.   All information obtained during the course 
of this study is strictly confidential. Data that may be reported in scientific journals 
will not include any information, which identifies you as a patient in this study. We will 
ONLY have your name on this informed consent form but will give your blood tubes a 
dedicated UNIQUE number so that you will not be identified in any way.  Prof Pretorius 
and the team will only use the unique number in the data analysis. Samples that are 
not fully used, will be stored under the unique number for  future (repeat or similar) 
tests. 
 
What will happen in the unlikely event of some form injury occurring as a direct 
result of your taking part in this research study? 
Neither you nor your medical scheme will be expected to pay for the study.  During a study-
related injury, the Department of Physiological Sciences/ Prof Pretorius assume no obligation 
to pay for the medical treatment of other injuries. You may discuss this in detail with your 
medical practitioner or Pathology Laboratory who have insurance for injuries that might occur 
during routine blood drawing practices. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No you will not be paid to take part in the research study.  
If your medical practitioner requests the personalized biomarker and coagulation 
analysis, payment will be done via the SUNguis system. 
 
Is there anything else that you should know or do? 
 You can contact the Health Research Ethics Committee at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by 
your study doctor. 
 If you request it, you will receive a copy of this information and consent form for 
your own records. 
 
 
Age: 
Gender 
HbA1c levels: 
 
 
Cholesterol levels: 
 
 
Other medication used: 
Stellenbosch University https://scholar.sun.ac.za
 87 
 
 
 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study “Circulating inflammatory biomarkers and dysregulated coagulation in 
inflammatory conditions 
OR because  my medical practitioner requested a personalized biomarker and/or 
coagulation analysis via the SUNguis incubator blood laboratory. 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor 
or researcher feels it is in my best interests, or if I do not follow the study 
plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
 
 
 
 ..............................................................   .......................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
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 I did/did not use a interpreter.  (If a interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
 
 
 
 ..............................................................   .......................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place) ......................…........…………….. on (date) 
…………....……………….. 
 
 
 
 ..............................................................   .......................................................  
Signature of interpreter Signature of witness 
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